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ABSTRACT 
HORMONAL CONTRACEPTIVE USE AMONG ACTIVE DUTY ARMY 
SERVICEWOMEN.  
TRENDS AND IMPLICATIONS FOR RISK OF MUSCULOSKELETAL INJURY. 
 
MAY 2018 
 
MELANIE K. HOSKER B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
B.S., UNIVERSITY OF NEBRASKA MEDICAL CENTER 
 
MPAS, UNIVERSITY OF NEBRASKA MEDICAL CENTER 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Brian W. Whitcomb 
 
 
Almost 40% of servicewomen use hormonal contraception every year, and 60% will use 
a contraceptive method in their military career. Rates of contraceptive use and musculoskeletal 
injury are higher among servicewomen as compared to civilians. Gender differences in rates of 
musculoskeletal injury have led investigators to question the role of sex hormones, including 
contraception. Recent studies suggest that hormonal contraceptives may decreased risk of anterior 
cruciate ligament (ACL) injury, potentially decreasing early onset osteoarthritis (OA). We 
utilized the Total Army Injury and Health Outcome Database, which prospectively captured 
demographics, clinical and pharmacy records on over 5.6 million Army soldiers since 1994. 
Hormonal contraceptive use was identified in the Pharmacy Data Transaction Service.  The first 
project described changes in covariates and contraceptive use overtime. Over the ten years of 
follow-up, there were increases in age, education, and rank of servicewomen at entry. Among 
contraceptive users, rates of pill use decreased from 79.71% in 2002 to 51.67% in 2011 with 
increased use of the ring, implant and IUD. Contraceptive users were young, higher ranking and 
more likely to be nulliparous. Education varied widely by contraceptive method with injection 
and patch users having the lowest and ring users the highest level of education. The second and 
third projects examined the association of hormonal contraceptive and ACL injury or OA by
vi 
 
survival analysis using multivariate Cox proportional hazards models. In project two, a total of 
2,253 incident ACL tears were identified from medical billing codes. In our final model, current 
users were 15% less likely to have incident ACL injury. Project 3 identified a total of 3,943 OA 
cases. In the final model, ever use of contraceptive was associated with a 19% reduced risk of OA 
compared to never users. Strengths of our study include the evaluation of all types of 
contraceptive use in a large, diverse, population-based cohort.  Information gathered from this 
study informs future studies considering hormonal contraceptives a modifiable risk factor for 
ACL injury and OA, informing contraceptive decision making, clinical recommendations, and 
injury prevention strategies for servicewomen particularly around key career events including 
basic training and deployment. 
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CHAPTER 1 
 
 
HORMONAL CONTRACEPTIVE USE: TRENDS OVER TIME 
Introduction 
The numbers of servicewomen and the roles they play within the Unites States military 
are ever changing and expanding. As of 1994, women were allowed to serve in 64% of 
occupational career fields and basic training was remodeled to train men and women side by side 
(HQDA G-1, 2014). As of September 2012, women served in 95% of all Army occupational 
career fields. In May 2013, the ban on women entering combat and infantry occupations was 
lifted and women were allowed to attend training for these positions (HQDA G-1, 2014). As of 
2010, women make up 20% of new recruits, 15% of active duty and 17% of reserve forces (Bean-
Mayberry et al., 2010). Rates of field grade (O-4+, Major+) and senior enlisted (E7-E9, sergeant 
first class to first sergeant) female leaders have increased over the past decade emphasizing the 
growing leadership roles women hold (HQDA G-1, 2014). Given the growing numbers of women 
across the roles of the military, assessments of women’s health issues are of increased importance 
as gender neutral standards are considered and women are integrated into combat positions. 
Historical Contraceptive Use by Servicewomen 
Historically, the use of hormonal contraception by servicewomen has been highly 
controversial. Military restrictions on intimate relationships while deployed, the geographical 
separation of servicewomen from their spouses during deployment, religious beliefs, and 
historically limited access to contraception have contributed to controversy. Three decades ago, 
epidemiological research within the military started to focus on gender differences in access to 
health care, reasons for clinical encounters and implications to a servicewoman’s ability to 
complete her job without timely access to care (Cobb, 1987). In the survey they distributed at 
medical clinics, including 750 women, there was a limited focus on hormonal contraception, 
 2 
though about 43% of the women surveyed were using oral contraceptives, 3% were surgically 
sterile and 2% were using an intrauterine device (IUD) (Cobb, 1987). Even with 50% using a 
contraceptive method, the need for evacuation of servicewomen from deployments due to 
pregnancy was considered to be the greatest threat to female troops during the Persian Gulf 
conflict. (Gallagher, Lall, & Johnson, 1997). Reports suggest that around 55% of pregnancies in 
servicewomen are unintended pregnancies (Duke & Ames, 2008; Chung-Park, 2007) similar to 
civilian counter parts. Although these three small studies (n=158, n=10 and n=52) focused on 
pregnancy, they identified correlation with knowledge and support with contraceptive use. They 
also identified barriers to use including association with promiscuity (Gallagher et al., 1997; 
Chung-Park, 2007; Duke et al., 2008). The goal of this research was to inspire educational 
interventions to decrease unintended pregnancies while on active duty, given the widespread 
implications for unit training, operations and readiness.  
Contraceptive Type and Frequency of Use Changes Over Time 
According to a summary report by Guttmacher Institute (2016), 62% of women 15 to 44 
years old are currently using a reversible contraceptive method including barrier methods. Based 
on 2012 reported use in the last month, 44.6% were using hormonal contraception, 25.9% used 
the pill, 10.3% used the IUD, 4.5% used injection, 2.0% used the ring, 1.3% used the implant and 
0.6% used the patch. The oral contraceptive pill was the most common method used among 
women, with 80% of sexually active women ever using the pill. The pill was used most 
commonly among white, young, single women with college education and no children. Women 
who were married were more likely to use any form of contraception compared to single women 
(77 vs 42%). IUD users were more likely to be 25-34 years old and parous. Between 2002 and 
2010, they found a 10 fold increase of ever use of the patch (1 to 10%). There was also a steady 
increase in long activing reversible contraceptives (IUD and implant) with 2% use in 2002, 6% in 
2007, 9% in 2009 and 12% in 2012. It is also notable that even among women who were sexually 
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active 52% were using contraceptives for non-contraceptive reasons including menstrual pain, 
menstrual regulation and acne. Similar research evaluating trends of contraceptive use, including 
all types, has not been published within the military though it is expected patterns would mirror 
that of their civilian counterparts (Guttmacher Institute, 2016).  
Contraceptive Use Varies by Key Demographics 
In the 1990s, Means-Markwell and colleagues noted the increasing use of other hormonal 
contraception types other than the pill, compared to a decade prior. In their survey including 628 
women, they reported that 29% of servicewomen used oral contraceptive pills on Navy ships and 
14% reported using depo injections (Means-Markwell et al., 1998). In 2010, Enewold and 
colleagues were the first to utilize the Pharmacy Data Transaction Service (PDTS), rather than 
using a survey, to quantify use of oral contraception by servicewomen and by military branch 
(Enewold et al., 2010). They considered a 12 month period of oral contraceptive use starting on 
October 1, 2004 including women on active duty (n=24,510) between the ages of 18-39. They 
found that OC use was significantly higher in the military than in the civilian population (34.4% 
versus 29.4%, p=0.05) for women greater than or equal to 20 years old, with an increasing 
difference with age. In addition, OC use was higher among married military women than married 
civilian women (34.0% versus 24.7%). There were racial differences noted as well with non-
Hispanic white women having the highest use at with 32.2% servicewomen using contraception 
versus and 19.8% of the general population. However, among women that were 18 or 19 years 
old, the prevalence was lower in the military (33.2% versus 40.6%). The Army had the lowest OC 
use by any branch at 29.9%, 9% less than the Air Force and 5% less than both the Navy and 
Marines (Enewold et al., 2010). 
Contraceptive Use Changes by Career Events 
Differences in demographic composition as well as varying training intensity and 
demands may partially explain observed differences in contraceptive use among branches of the 
 4 
military (Army, Marines, Air Force, Navy and Coast Guard). In addition, within a given branch, 
patterns of use may change around key career events including basic training and deployment (as 
compared to a home station in the U.S.).  Prior studies suggest a decline in contraceptive use after 
entry into the military as well as during deployment (Holt, Grindlay, Taskier, & Grossman, 
2011). Changes in training environment, location and duration may impact contraceptive choice 
for many reasons. Battista and colleagues reported use of contraceptives, as self-reported on a 
questionnaire, prior to and during basic training (BCT) among 564 soldiers, including 244 
women, attending Army medical specialist training in Texas during January 1998. Compared to 
use before basic training, reported abstinence increased from 15.9 to 26.7% (p<0.001) and 
women not using any method increased from 5.6% to 12.3% (p=0.005). Oral contraceptive pill 
use dropped by half 30.5% vs 15.7% respectively (p<0.001) once women started basic training 
(Battista, Creedon, & Salyer, 1999; Holt et al., 2011). Of the 222 women surveyed, 62 (28%) 
requested a prescription for a contraceptive method. Of those, only 37% were able to obtain it, 
32% were told a pelvic exam was required and no appointments were available, and 26% were 
advised they did not need contraception during basic training or to wait until their next duty 
station (Battista et al., 1999).  
In 2013, Grindly conducted an online survey including current servicewomen and 
veterans (n=281) to assess contraceptive use during deployment. Almost 60% of servicewomen 
reported they did not speak with a provider about contraceptive options before deployment. Of 
those who required refills while deployed, one third said they could not access the method they 
wanted, and 41% found it difficult to obtain refills (Grindlay & Grossman, 2013). Nielsen and 
collages conducted a survey among deployed servicewomen in Iraq between August 2005 and 
March 2006. Of 397 surveyed, 44% reported using some type of hormonal contraceptive. 
However, 43% said they changed their method because of availability (Nielsen et al., 2009). In 
2011, Holt and colleagues summarized reported use of contraceptives among eleven studies and 
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found that the overall prevalence of current use of contraceptive methods was 55-88% among 
soldiers stationed in the U.S. as compared to 39-77% among deployed soldiers (Holt et al., 2011). 
Two additional studies conducted during Operation Iraqi Freedom (OIF) using survey data, one 
collected from 251 women at a primary care clinic, the other from 397 women at an combat 
support hospital between 2005-2006, suggest that between 23-42% of women will change 
methods during deployment due to lack of availability (Nielsen et al., 2009; Thomson & Nielsen, 
2006). In addition, in two surveys including 397 and 500 women, between 16-44% will forget to 
take or replace a contraceptive dose at the correct time and about 50% of women report patches 
falling off due deployment conditions (Nielsen et al., 2009; Thomson & Nielsen, 2006; N. 
Powell-Dunford, Cuda, Moore, Crago & Deuster, 2009). Recent literature reviews and research 
between 2002 and 2011 seeking to optimize readiness of servicewomen recommend that 
clinicians allow at least a 3 months and preferably a 6-12 month supply of hormonal 
contraception be dispensed to women  expecting to be deployed (Bean-Mayberry et al., 2010). 
Goyal et al. noted that about 10% of women who are deployed will not use the prescription 
(Thomson et al., 2006). Concerns and tolerance for side effects (perceived and experienced) may 
also vary by career events. Common side effects that were noted as concerns included nausea, 
weight gain, headache, and irregular bleeding. The inconveniences of these side effects can be 
exacerbated during long shifts in harsh climates especially if they are unexpected (Goyal, 
Borrero, & Schwarz, 2012).  
Physiological Implications of Use 
Hormonal contraceptives are frequently used, regardless of whether a woman is sexually 
active, to treat menstrual symptoms and regulate or suppress menstrual cycles. Hormonal 
contraceptive use is impacted by the availability of clinical care and has been associated with 
both potentially beneficial and detrimental physiological impacts. Exogenous hormones from 
contraceptives impact follicle-stimulating hormone (FSH) and luteinizing hormone (LH) surges 
 6 
mid-cycle as well as provide a predictable dose of estrogen and progesterone. The physiologic 
changes associated with contraceptive use vary between individuals and by contraceptive type 
and dose. Many contraceptives provide potential reduction in pre-menstrual syndromes, shorten 
menses, regulate or suppress a menstrual cycles. Hormonal contraceptives are also used for 
treatment of polycystic ovarian syndrome, as well as prevention of anemia and acne (Enewold et 
al., 2010). Contraceptives may also alleviate some of the symptoms that are reported to interfere 
with physical activity (including menstrual cramping) to enhance performance (Schneider, Fisher, 
Friedman, Bijur & Toffler, 1999) and an early study by Mӧller-Nielsen and Hammar in 1989 
suggested contraceptives may reduce risk of traumatic lower extremity injury. In addition, 
contraceptives are suggested to play a role in prevention of the female athlete triad, a condition 
that occurs among young active females and includes bone loss, amenorrhea and low caloric 
intake. However, hormonal contraceptives are known to increase risk of cardiovascular disease, 
especially among smokers, as well as potentially increase risk for cervical and breast cancer 
(Enewold et al., 2010). It is important to consider the potential benefits, consequences and 
motivations for use by type of contraception among servicewomen who are generally young and 
active.  
Changing Motivation for Use 
The desire for contraceptive induced amenorrhea among service women has increased 
due to high frequency deployments in austere environments over the past decade. Continuous use 
of many contraceptive methods inhibits menstruation, and also can reduce headaches, 
dysmenorrhea, length of cycle and protect against anemia. In addition, the burden associated with 
sanitary product storage, hygiene and disposal, which may be avoided with induced amenorrhea, 
is reported as a substantial problem among servicewomen (N. C. Powell-Dunford, Deuster, 
Claybaugh, & Chapin, 2003). In 2001, Powell-Dunford and colleagues surveyed 154 U.S. Army 
active, Reserve and National Guard servicewomen. Over 80% of women surveyed desired 
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amenorrhea during deployment or training, but only 54% were aware that pills could suppress the 
menstrual cycle and only 7% actually used pills to suppress their cycle during a prior deployment 
(N. C. Powell-Dunford et al., 2003). A more recent study found that about 40% of women used 
contraceptives during deployment and about half of those used continuous methods (N. C. 
Powell-Dunford et al., 2011). Continuous use has potential advantages for servicewomen, 
especially during deployment, but requires women receiving contraceptive counseling and 
uninterrupted access to their continuous method of choice while deployed.  
Summary 
Servicewomen make up a young active population that has potentially greater access to 
contraception due to the full insurance coverage they receive from TRICARE while on active 
duty. They may be encouraged by medical providers to consider contraceptive use for menstrual 
suppression during deployments and training. The integration of women into previously male 
only combat roles may further increase consideration of use of contraceptives for menstrual 
suppression and pregnancy prevention. 
Over the past thirty years many studies have utilized small convenience samples to assess 
contraceptive knowledge, use, changes and prevalence among servicewomen. These studies 
include women in all military branches, of all ages and stages of their career. However, diversity 
among studied populations, varying methods of data collection (including both self-report and 
pharmacy records) and inconsistency in the detail of contraceptive classification, has led to a lack 
of clear conclusions regarding changes of contraceptive use at a population level from the 
research to date. Changes in contraceptive use over time are important to consider in relation to 
other outcomes including pregnancy rates, musculoskeletal injury as well as establish baseline 
rates of use prior to participation of women in combat positions. In the only study to date to 
quantify contraceptive use at a population level within the Army (Enewold, 2010) using PDTS 
dataset among n=24,510 Army servicewomen, oral contraceptive use assessment was limited to a 
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dichotomous yes/no. Military rank, education and parity were not considered as potential 
predictors of use. In addition, 12 month yes/no capture of contraceptive use does not allow for 
consideration of changes in use and type over time.  
Given the increasing participation of older, college educated women in the military as 
well as changes in the frequency of deployment and acceptability of long-acting reversible 
contraceptives, the prevalence reported by Enewold may not be accurate as a current assessment 
of contraceptive use in this population. Increased attention toward education programs in the 
Army surrounding contraceptive use along with changing demographic profile and increased 
social acceptability of long term contraceptive methods may have also led to altered use, and 
further supports the need for a contemporary assessment with more up-to-date data sources.  
A large-scale descriptive study of hormonal contraception use by servicewomen could 
provide critical insight to how use may be related to key career events, as well as identify 
predictors of contraceptive use by type and regularity of use. Regardless of whether a woman is 
sexually active, hormonal contraceptives are commonly used among young reproductive aged 
women and have significant social, medical and physiological implications that may affect her 
ability to meet fitness and occupational standards. Therefore, it is important to establish a baseline 
of hormonal contraceptive use and correlates especially if sub-groups are identified to be at high 
risk for methods change or non-use. Contraceptive use is one key factor that cannot be ignored as 
women are integrated into previously male only occupational positions, for health care planning, 
and hypothesis generation for future analysis 
Aims and Hypotheses 
 The overall objective of this study was to characterize the demographic profile of 
servicewomen and their use of contraceptives over time between 2002 and 2011 using the Total 
Army Injury and Health Outcomes Database (TAIHOD).  
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Specific Aim 1 
To evaluate changes in contraceptive use among active duty servicewomen over time. 
Hypothesis 1: Compared to 2002, prevalence of alternative contraceptive methods (seasonal 
contraception, patch, ring, injection and implant) use will have increased as of 2011. 
Specific Aim 2 
To evaluate difference in key demographics among active duty servicewomen who use 
hormonal contraception. Hypothesis 2: Compared to soldiers who are enlisted and soldiers who 
do not have a college education, officers and college graduates will have higher prevalence of 
contraceptive use. 
Specific Aim 3 
To evaluate changes in contraceptive use surrounding key career events including basic 
training and deployment. Hypothesis 3:  Compared to permanent station, women will experience 
lower prevalence of contraceptive use during basic training and deployment. 
Methods 
Study Design and Population 
The study population consists of servicewomen between the ages of 17 and 45 who 
served at least two months on active duty between January 1st, 2002 and December 31st, 2011 
using the TAIHOD. The TAIHOD was created in 1994 with the aim to study injuries among 
female soldiers, though the database captures servicemen and women. The database prospectively 
links administrative, clinical, pharmaceutical, occupational and health behavior data for all 
soldiers who have been on active duty. The TAIHOD currently contains data on over 5 million 
soldiers with active service and outpatient clinical records as far back as 1997. For the current 
study, the start date of January 1st, 2002 was selected as it marks the onset of electronic 
pharmacy record capture from the PDTS, which is integrated into the TAIHOD to determine 
hormonal contraceptive use. This timeframe captures Operation Enduring Freedom and Operation 
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Iraqi Freedom (OEF/OIF), which allows for evaluation of changes in contraceptive preference 
and use in austere environments as well as changes in number and frequency of deployments. 
Exclusion 
For the purpose of the current study, women with only one record in the DMDC were 
dropped due to the insufficient observation time to capture and quantify hormonal contraceptive 
use, changes in duty station and other undetermined cause for military discharge that make these 
women not generalizable to the active duty women who serve for longer periods of time. In order 
to restrict consideration to pre- and not peri-menopausal women, women were censored from the 
analysis at the age of 46. Thus, women who entered the cohort at age 46 did not contribute any 
observation time to the study; however, women who turned 46 during the study timeframe 
contributed person time up until censoring at age 46, with subsequent person time dropped. 
Participants who were missing age, education, marital status, race or ethnicity from the DMDC 
were excluded. From this population, we further excluded women who had medical record 
documentation of a hysterectomy, oophorectomy, clinically diagnosed menopause, or used 
hormone replacement therapy as these women likely have different comorbidities that may 
impact their use of hormonal contraceptives (Appendix A). In addition, women who experienced 
one of these events during the study cohort were dropped at the event date and person time 
following the event was also dropped. Women with greater than 120 pregnancy visits during the 
study cohort were also excluded. These women compromise a group of either implausible 
medical records or high risk pregnancies that are likely not generalizable. The number of women 
and person years excluded and dropped are shown in Table 1. 
Contraception Use, Timing and Duration 
Hormonal contraceptive use was assessed through pharmacy data recorded in the PDTS 
within the Medical Data Repository. The PDTS is a complete database capturing all prescription 
pick-ups at Military Treatment Facilities, TRICARE pharmacy networks, and mail orders 
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(Department of Defense, 2009; The Department of Defense Pharmacoeconomic Center, 2011). 
Pharmacy records contain information on: therapeutic class, product name, type of hormonal 
contraceptive, dosage, days’ supply, quantity and date pick up. TRICARE covers hormonal 
contraceptives at no cost to soldiers (Enewold et al., 2010). Therapeutic class codes ‘681200, 
contraceptives’ and ‘683200, progestins’ were used to identify hormonal contraception. 
Prescriptions recorded with a dispense quantity equal to zero were considered as requested but 
not picked up. Prescriptions for HRT or treatment for amenorrhea and anovulation were not 
included in the analysis as hormonal exposure.   
Statistical Methods 
To evaluate the impact changing demographics may have on use of contraceptives, key 
variables were assessed and compared across ten year-long intervals during the study period 
using chi-square and ANOVA. Because of the large sample size, p-values were only reported if 
they were not statically significant (p>0.05) (Table 2). Demographics at entry into the study 
cohort were reported in a summary entry column. This column represents the first available 
demographics captured for each woman. For women who served prior to the study cohort, this 
represents their demographics as of January 2002. For women who joined the cohort as a new 
accession, this represents their demographics at the date of entry into the Army. The annual 
covariates represent the last record for each servicewoman in the given year. 
Contraception Types 
The PDTS dataset contains information on the date, quantity and contraceptive type 
dispensed. Product type other than: pill, patch, injectable, implant, vaginal ring were eliminated. 
Exposure was further categorized by type of contraceptive to evaluate differences in use of 
combined hormonal contraceptive versus progestin only. Combined hormonal contraceptives 
included monophasic, biphasic and triphasic oral contraceptives, Ortho-Evra (birth control patch), 
and Nuvaring. Progestin only contraceptives include progestin only pill, Depo-Provera 
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(injection), Mirena (intrauterine device) and implants (including: Noroplant, Implanon and 
Nexplaon). Timing and duration of use was determined from start and stop dates were calculated 
as follows: start date equals date of pick up plus one day and the end date is equal to the start date 
plus the quantity provided.  
For consistency with prior literature, the initial analysis was performed using any 
hormonal contraceptive with dichotomization into ever versus never user. Additionally, we 
considered use as ‘never’, ‘past’ and ‘current’, contraceptive type, as well as cumulative exposure 
in months on any contraception within the study timeframe. A servicewoman’s first ever and last 
contraceptive pick up during her career were presented in summary columns. Annual 
contraceptive use was determine by last contraceptive pick up in a given year among women who 
used any contraception during the year. Chi square and ANOVA were used and p-values were 
only reported if they were not statically significant (p>0.05) (Table 3).  
It is important to note that women remain in the dataset multiple years and thus the same 
woman contributes her contraceptive status and demographics every year she is present in the 
database. It is also possible for a soldier to change her contraceptive type within a year. This 
information would not be captured in this table based on the hormonal contraceptive type 
definition used. A servicewoman may be on two types of contraception for a short duration of 
time (for example implant and pills) when transitioning between methods or when treating 
undesirable side effects of one method with another. In our study, it was assumed when a woman 
picked up a new contraceptive method that she stopped the previous method. Non-hormonal 
barrier methods including the diaphragm, condom and spermicide use were not be considered in 
this analysis. Paragard IUDs are non-hormonal methods and during use women were considered 
to be not exposed. Correlates of hormonal contraceptive use and demographics were evaluated 
based on ever versus never user and additionally stratified by first type of contraceptive method 
ever used (Table 4).  
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Contraceptive use was also compared at four key time points during a servicewoman’s 
career: basic training, deployment, permanent overseas station and home station in the U.S. Basic 
training was identified as the first duty station of an enlisted servicewoman’s career, typically the 
first 90 days. For enlisted women who entered the Army prior to 2002, their basic training was 
assumed to have been completed in the past. Deployment and overseas station dates were 
assessed from records including country name, start and end dates. Duration of time overseas was 
calculated based on start and end date. Frequency and duration of each event and associated 
contraceptive use was presented (Table 5). Change in contraceptive use relative to the BCT, 
deployment, overseas and home duty station were categorized into mutually exclusive categories: 
never user, started contraceptives, stopped contraceptives, changed contraceptive type, used one 
type of contraception the entire time (Table 6). 
Combined Hormonal Contraception (CHC) 
Oral contraceptives and emergency contraceptives were identified by a pill product type. 
Emergency contraceptives were identified by product name (“Ella” “Next Choice”, “Plan B”, and 
“Plan B One-Step”) and were excluded. These products contain varying levels of progestin (0.75-
30 mg) and two different types (ulipristal acetate and levonorgestrel). There are over 90 types of 
oral contraceptives dispensed between 2002 and 2011. Contraceptives were classified as: 
combined hormonal (including monophasic, biphasic and triphasic) and progestin only by product 
name and therapeutic class code.  
 Only one type of contraceptive patch is distributed to service members (OrthoEvra). This 
patch has a standard dose of 0.75 mg EE/week and 6 mg of norelgestromin/week making it a 
combined hormonal contraceptive method (RegenceRx, June 2012). For three consecutive weeks 
a single patch is worn for seven days then replaced with a new patch. The fourth week of this 
prescription is a no patch week which is when the woman experiences menstrual bleeding. 
Therefore, a quantity of three patches dispensed is equal to one month (28 day) supply.  
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NuvaRing is a contraceptive ring that has a standard dose of 15 mg EE/day and 0.12 mg 
of etonogestrel/day making it a combined hormonal contraceptive method (RegenceRx, June 
2012). For three consecutive weeks one vaginal ring is used. The fourth week of this prescription 
is a no ring week which is when the woman experiences menstrual bleeding. Therefore, when one 
ring is dispensed it is equal to a one month (28 day) supply.  
Progestin Only Methods 
DepoProvera (“Depo”) is the brand name for contraceptive injection. Depo is 
administered by one injection every 12-14 weeks with a dose of 104mg subcutaneously or 150mg 
intramuscularly of medroxyprogesterone acetate making this method progestin only (Cerner 
Multum, 2013). There is no break between injections for menstrual bleeding, therefore this 
method is used continuously. Medroxyprogesterone acetate is also used for treatment of 
endometriosis (same dose as subcutaneous), amenorrhea (with 5 to 10 mg oral tablets for 5 to 10 
days), both of which were not included in contraceptive exposure classification.  
Contraceptive implants were identified by the product type: implant. Possible brand 
names include Implanon and Nexplanon. The contraceptive implant is inserted during an 
outpatient office visit and can remain in place up to 3 years. Start dates of contraceptive implants 
were obtained by comparing pharmacy and clinical encounter dates, procedure code for insertion. 
End date of implant use was determined by clinical encounter procedure codes for implant 
removal. Contraceptive implants release 68 mg etonogestrel over 3 years making this method 
progestin only (RegenceRx, June 2012).  
Intrauterine devices were identified by clinical encounter procedure codes for insertion 
and removal. An IUD is inserted during an outpatient office visit and can remain in place up to 5 
years for Mirena. Mirena releases 20 mcg of levonorgestrel per day making method progestin 
only (RegenceRx, June 2012). The Healthcare Common Procedure Coding System (HCPCS) 
provides procedure codes that are intended to distinguish Mirena (J7302) from Paragard (J7300).  
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Validity of Exposure 
Hormonal contraceptive pharmacy records have not been validated in the TAIHOD. 
However, in previous research pharmacy records are suggested to be a valid source of 
information regarding use, duration and timing of contraceptives when compared to self-report 
(which is the most frequently utilized method of exposure assessment), with correlation 
coefficients ranging from 0.84-0.93 (Norell, Boethius, & Persson, 1998). Discordance between 
pharmacy records and self-report may result from inaccurate self-reporting, or when prescriptions 
are filled but not used. Pharmacy records are suggested to be a more accurate source of 
information than self-report regarding type of oral contraceptives (high dose, low dose and 
progestin only pill) (Norell et al., 1998). Use of pharmacy records for assessment of duration of 
use requires assuming that any prescription dispensed was used for the entire days’ supply as 
directed by the pharmacy. Inaccuracy in duration of use may result depending upon whether 
women use the week of inactive pills from a 28 day supply (in which case, the total number of 
pills equal duration) or if they discard the inactive pills and begin a new pack of pills to electively 
suppresses (or skip) her menstrual cycle (in which case, duration as determined from pharmacy 
records of supply overestimates actual duration of use by one week per 28 day supply).  
Covariate Assessment 
Demographic data including age, race, ethnicity, education, marital status, grade and 
length of service were extracted from the monthly DMDC data repository. When a service 
member joins the military without any previous military they are considered to be a new 
accession. For new accessions, length of service represents any time on active duty in the study 
cohort between 2002 and 2011. For women with active duty time prior to 2002, length of service 
a sum of all time on active duty prior to and including the cohort timeframe  Ever attendance to 
BCT was identified from training records, however, dates of BCT were determined as discussed 
above. Deployment records and overseas station dates and location were merged in with DMDC 
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records. A single measurement of body mass index (BMI), as measured at accession, was also 
merged with the demographic data.  Diagnostic and medical procedure billing codes from the 
time a woman entered active duty were available and utilized to identify lower extremity injury 
and delivery (Appendix A). Records for women who served on active duty prior to 2002 were 
included to capture the number of deliveries and lower body injuries prior to the cohort. Parity 
was determined by the number of dependents, marital status, age and delivery during the study 
cohort. Women with a known delivery during the study are automatically parous. Women without 
any documented deliveries, but were married with 2 or more dependents were also considered 
parous. Women who were, single with no dependents were considered nulliparous.  
Results 
Final Study Sample 
Exclusions are detailed in Table 1. Of the 207,777 participants and 757,610 person years 
of total observation, the most common reason for exclusion was due to missing records 
(n=6,220). Over one third of those excluded (n=3,544) only had one month record in DMDC. An 
additional 2,676 women were missing age, education, marital status, race or ethnicity. An 
additional one percent of women were excluded from the study due to being age 46 or older at 
entry to the cohort or to the Army. Less than one percent of the study population were excluded 
due to a medical reason. Half of the women excluded at entry and 79% of the women dropped 
during the study time frame had service prior to 2002 (Table 1). 
Demographics of Servicewomen 
As shown in Table 2, an average of 82,000 women were on active duty in a given year 
(ranging from 80,504 to 84229) and on average 15% (12.57-17.18%) of these women are new 
accessions with about 9,000 women attending basic training every year. The average age at entry 
into the cohort was 23. More than 70% of women had less than high school level education (or 
equivalent) at entry to the Army, though the average age (26.46 to 27.86) and education level 
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(18.29 with college or graduate school to 22.77%) of servicewomen increased during the follow-
up period. The proportion of women married as well as the average rank paralleled increasing age 
and education. Most women were enlisted members ranking E1-E9 (E1-Private through E-9 
Sergeant Major) with 10% of women holding an officer position (Warrant Officer or 
Commissioned Officer) at entry to the cohort. The percentage of servicewomen identifying as 
African American declined 6% between 2002 and 2011. The average length of service was 3.5 
years with the proportion of women serving 4 to 8 years doubling between 2002 and 2011. One 
quarter of the population was deployed in any given year with more than half ever deploying by 
the end of the follow-up. Equal portions of women were nulliparous/parous in a given year with 
40% of women delivering while on active duty. At the start of the cohort, few women had a prior 
documented injury. However, by the end of the follow-up more than 50% of women had 
experienced a knee injury, 30% sustained a back injury and 15% sustained an ankle injury. Over 
57% of women had a BMI in the normal range (18.5-25 kg/m2) at entry with less than 6% 
comprising extreme BMI categories underweight (<18.5 kg/m2) or obese (>30 kg/m2). More than 
89% of women filled a prescription for NSAIDs during the study follow-up period (Table 2). 
Contraceptive Use Over Time 
As shown in Table 3, 60% of women on active duty between 2002 and 2011 used 
contraceptives by the end of follow-up. In a given year, use of hormonal contraception was over 
40%, peaking 47.71% in 2006. Over the ten year period of observation, oral contraceptives 
remained the most frequently used method although the rates declined by 28% over follow-up. 
The contraceptive patch was popular in 2003-2006 with use over 10% that declined below 5% by 
the end of follow-up. Use of the vaginal ring was not common in 2002, however by the end of 
follow-up over 8% of contraceptive users selected this method. Rates of implant and IUD use 
increased overtime. Between the first type of hormonal contraceptive and last type, before a 
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servicewoman stopped using or was censored at the cohort end, there was a 6% decrease in pill 
use where women were more likely to use the ring, patch, IUD or implant (Table 3). 
Correlates of Contraceptive Use 
Compared to servicewomen reporting never having used contraceptives, women with 
ever use of contraceptives during the cohort were on average 1 year younger, had lower rates of 
college education, and were more likely to be single, nulliparous women with a shorter amount of 
time in the cohort. Ever users were less likely to have a known prior knee injury and more likely 
to have a back, hip, leg or ankle injury. IUD use was higher among older, married officers than 
women who chose the contraceptive implant. Over 75% of injection and implant users had only a 
high school education or equivalent compared to ring users having over 24% with completion of 
college or graduate school. The patch and injection were used more frequently by African 
American soldiers compared to other methods (Table 4). 
Contraceptive Use by Career Event 
Comparisons of contraception use and type by career events, including basic combat 
training, home station, first deployment, and first duty station overseas station, are shown in 
Table 5. Usage of contraceptives was highest for overseas station at 72%. While stationed in the 
U.S., 60% of servicewomen used some method of hormonal contraceptive, similar to 63% usage 
during deployment; whereas, only 9% use contraception at basic combat training. Among 
servicewomen, use of contraception, methods of use were largely similar across career events 
with a few notable differences. Among users of contraception at basic training, rates of depo 
injection use was 7% higher as compared to users of contraception at home station. During their 
first deployment, women were slightly more likely to use hormonal contraceptives, with a 
preference towards combined hormonal contraceptive pills and decreased use of the vaginal ring 
compared to use at the home station (Table 5). 
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Changes in Contraceptive Use By Career Event 
Table 6 compares contraceptive use while stationed in the U.S. to any other career event. 
Servicewomen were more likely to start and change contraceptive types while stationed at home 
(33.45% and 21.73% respectively). During basic training, few women used contraceptives and of 
those who used contraceptives 71% started use during this timeframe. Women who were 
deployed or who were stationed overseas were more likely to stop their contraceptive type and 
also had higher rates of using one type the entire duration of the event as compared to women 
who were stationed in the United States. Over time, the number of women stationed in the U.S. 
who stopped a method and who used a single type of contraceptives increased. Rates of women 
who started a contraceptive type while stationed in the U.S. remained high.  On a yearly basis, the 
rate of staying on one method increased during deployment and overseas station, while stopping a 
method was variable between years (Table 6). 
Discussion 
Summary of Findings 
More than 60% of women had documented contraceptive use during the 10 year cohort. 
Oral contraceptives were the most popular, though over time an increased preference for 
alternative methods include the ring, implant and IUD were observed. Ever contraceptive users 
were more likely to be young, single nulliparous women at entry to the Army. IUDs were 
preferred among older married women whereas the injection and implant were preferred by 
younger women.  
Hormonal contraception was rarely used during basic training and more frequently used 
while overseas as compared to home station. Women stationed overseas were more likely to stop 
and not restart a contraceptive method compared to women stationed in the U.S. 
The annual cohort size of women in the Army remained relatively stable between 2002 
and 2011. Over the cohort, the average age, education and rank increased. Few servicewomen had 
 20 
a known prior knee injury at entry, over 50% had a knee injury during the study.  In addition, it is 
important to note that by 2011 more than 89% of women ever received a prescription for NSAIDs 
during the cohort. Although it is not possible to identify the reason for NSAIDs use, it is possible 
that users, especially frequent users, may represent women who have a lower extremity injury, 
diagnosed or undiagnosed, or may represent more active women. 
Implications of Main Findings 
Overall, rates of hormonal contraceptive use were high in this young, active population. 
The ten year follow-up period captures a unique socioeconomic time where new contraceptive 
types were introduced to the market. In 2000, the FDA approved Mirena which replaced the 
Dalkon shield. Initially, Mirena was a popular method among parous women, however, the social 
acceptance for both patients to request and providers to insert the IUD in young nulliparous 
women has continued to increase over time. In late 2001, the FDA approved both Ortho Evra and 
Nuva Ring, giving women a chance to choose weekly or monthly methods rather than daily pill 
use. The five rod implant, Noroplant, was no longer distributed after 2002 though supplies 
remained and Implanaon was approved in 2006. The depo injection has been available for 
decades and may be preferred by patients who would like high efficacy method that minimizes 
daily, weekly or even monthly forgetfulness. Depo may be encouraged for younger women by 
providers because it does not rely on perfect use by the patient.  
New accessions were more likely to use the ring and implant which may demonstrate 
temporal changes in availability with the introduction of these methods. Enlisted women were 
more likely to use the injection and implant as their first method which may represent social 
acceptance of the new contractive type but also potential encouragement from the provider to as 
discussed. 
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Findings in Comparison to Prior Studies 
Enewold and colleague reported rates of oral contraceptive use in a given year to be 
around 30% in the Army (Enewold et al., 2010). Our database included an additional nine years 
of data and suggest that 60% of women have ever used hormonal contraception. Enewood’s study 
was limited to oral contraceptive use only. When looking at last method of use, we found that 
36.5% of women used oral contraceptives, higher than the 30% presented by Enewold. Our study 
adds to the literature by including the addition methods of use and changes in use over time. We 
observed that over time an increased preference for long acting reversible contraceptive methods 
occurs which mirrors the increase in acceptance of these methods among civilian counterparts.  
Enewold and colleges also identified difference in contraceptive use by age, race and 
marital status. They found the highest rates of oral contraceptive use among married women and 
women between 25-29, 10% more than women less than 20 and or over 35 years old. They also 
noted that non-Hispanic white women had the higher rates overall use at 35%, 7% more than non-
Hispanic black women. Our results, which considered demographics at entry into the cohort, 
suggest that contraceptive users were on average 1 year younger, on average 23 at entry to the 
Army. Use varied by marital status, and IUD rates were highest among older married service 
member and implant rates were more popular among younger single soldiers. This may be 
confounded by acceptance of IUD by women with prior pregnancy or by provider’s preference of 
IUD use in parous women in monogamous relationships. In addition, we also noted a differences 
by rates of patch and injection use by race with 10% higher proportion of African Americans as 
compared to pill use. 
A previous study, by Battista and colleague, suggested only 15% of women use the oral 
contraceptive pill during basic training (Battista, Creedon, & Salyer, 1999). We identified only 
5% of women using oral contraceptive method during basic training which may indicate we are 
missing women who arrived at basic training with their own supply of their contraceptive 
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method. Prior studies also suggest a decrease in contraceptive use during deployment, with only 
44% using a method and 43% changing methods (Nielsen et al., 2009). Our results suggest a 
much larger proportion of women are using some contraceptive method similar to estimates 
presented by Holt et al., in 2011 who reported 55-88% of women stationed at home use and 39-
77% of deployed women use contraceptives (Holt et al., 2011) (Table 5).  
Limitations 
Misclassification of Exposure 
Misclassification of the exposure is an important limitation to address in this study. This 
studies relies on pharmacy record pick-ups which assumes (1) all servicewomen use their health 
insurance to cover their prescriptions (2) all pharmacy perception pick-ups are used as directed 
(3) if two different types of birth control over lap the first is likely stopped at the time the second 
method is picked up. It is unlikely that rates of misclassification would vary by year with the 
exception of 2002. Contraceptive use prior to 2002 is not established in this study, therefore we 
acknowledge we are underestimating ever users as well as current users in 2002 until they picked 
up their next prescription. Prior studies suggest up to 10% of women forget or stop hormonal 
contraception while deployed and there may be variable rates of misclassification based on career 
event (Goyal, Borrero, & Schwarz, 2012). It is important to note that a large portion of many 
servicewomen’s reproductive career is not captured in the study cohort. Our results present cohort 
prevalence not lifetime prevalence.  
A survey by Esposito and collages estimated about 8% of military members had one 
unclaimed prescription in a the last year (Esposito, 2008). However, this is less likely with 
contraception as it is and elective prescription also we could be more confident that a woman is 
using at least most of her prescription if  the next refill is picked up on a monthly basis, or at the 
appropriate time point based on previously dispensed quantity. It would be unlikely that a woman 
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women fills 3 packs of pills, does not use them and returns to pick up another 3 months more that 
she does not plan to take. In these circumstances, contraceptive use would be overestimated.   
Though not a limitation to the study of hormonal contraception, it is also important to 
know that other contraceptive methods were used by soldiers and not captured in this analysis. 
These methods include barrier methods: condoms, diaphragm and spermicide. When considering 
contraception for pregnancy prevention, these methods are important to consider. However, these 
methods typically have no physiologic or clinical impact apart from adverse reactions (e.g. 
topical skin irritation and allergies) and unintended pregnancies.  
In 1983, a study was published in Military Medicine to examine use, understanding and 
adherence to contraceptives. From a sample size of 81 women, only 57% could recall the name of 
their contraceptives, 27% indicated they did not take the pill at the same time each day and 70% 
had forgotten to take at least one pill at least in the past month (Casey, Fluitt, & Wiatt, 1983). 
Self-discontinuation of contraception was not measured during our cohort as there is no 
integrated data on self-reported contraceptive use and is a notable limitation of this research. 
Pharmacy records provide the type, brand, hormone dose and duration of a prescription but fail to 
account for missed pills, lost prescriptions and cessation of use. 
Selection Bias 
Selection, or participation, bias is often an important concern for studies hormonal 
contraceptive use. Women who use contraceptives may be disproportionally represented at 
clinical encounters due to the need for prescription refills or they may be more oversampled in 
health care surveys given need to pick up prescriptions. However, these potential issues are 
unlikely to substantially affect the current study for several reasons. TRICARE covers the cost 
contraception for servicewomen. Also, both the pharmacy database and personnel records for the 
Army have 100% capture of soldiers on Active duty, it is unlikely that any women would be 
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missed for this analysis. This study provides a population level capture of contraceptive use 
among all servicewomen on active duty between 2002 and 2011.  
Incorrect Timing of Career Events 
It is possible that both BCT and deployments may not be accurately captured and 
therefore changes in contraceptive use linked to these time points may be inaccurate. In prior 
TAIHOD studies, basic combat training has been defined as most likely occurring within the first 
90 days of a soldier’s career. In addition, service members may go on other training including 
Advanced Individual Training, Officer Basic Training, and other temporary duty. The dates of 
theses trainings are not be captured in the TAIHOD. These trainings may require a soldier 
relocate for periods of a few weeks to a few months, often involve both physically and mentally 
challenging standards and could impact contraceptive use. Our analysis was limited in ability to 
assess contraceptive changes for BCT only and should not be extrapolated to all courses 
servicewomen attend. Deployment dates captured in the electronic data system represent 
mobilization date. However, this date does not always match the date in country. Service 
members may be assigned to in or out processing time in country before their in country 
deployment. Therefore, changes in contraception may occur around these times rather than while 
deployed.  
Strengths 
There are many strengths to our study that contribute to the growing body of literature. 
Most notably was our sample size. Only a few population or registry based reports have been 
published to date, only one including service members. This research not only presents complete 
capture of all servicewomen between 2002-2011, but it also utilizes pharmacy, deployment and 
training records to assess temporal changes in rates and type of use by key career events. The 
TAIHOD provides a unique advantage to asses this relationship given the large diverse 
population. In addition, we have captured all types of hormonal contraception including progestin 
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only pills, patch, ring, injection, IUD and implant. Almost all previous studies have failed to 
consider these methods in their analysis. Finally, our population is comprised of a healthy, active, 
closely monitored group. This allows for consideration of many covariates and sub classification 
of contraceptive use and type. 
Recommendations for Future Research 
There are remaining areas of interest that deserve additional attention and were not 
addressed in this study. Temporality of contraceptive use cessation and resumption around 
pregnancy was not evaluated but could provide windows of time with unique endogenous and 
exogenous levels of hormonal exposure. In addition, use of hormone altering prescriptions 
including Tamoxifen, or treatment for medical conditions including polycystic ovarian syndrome 
were not considered in this analysis. The frequency of dual use of contraceptives for purposes of 
changing methods or suppressing undesirable side effects was not considered in this paper. 
Servicewomen complete annual health exams that collect self-reported prescription use. This data 
was not included with TAIHOD at the time of data extraction, therefore, self-reported 
contraceptive validation was not possible. In addition, only a small fraction of the HCPCS coded 
for IUD insertions differentiated the type of IUD, Mirena or Paragard, which could also be 
gathered from self-reported prescription use at annual periodic health exam. 
It is important to consider the use of all contraceptive types and characteristics for a 
number of physiological, social economic and military readiness factors. From a physiologic 
standpoint, it is established that the total dose of exogenous hormones as well as the impact on 
endogenous hormones vary by contraceptive type. It is critical to include the additional 10-15% 
of women that are using a contraceptive type other than pills in a given year. Both the desirable 
(including decreased PMS and menstrual suppression) and undesirable (including weight gain) 
side effects vary by type of contraception and need to be considered in future research. 
Historically, there has been stigma (perceived promiscuity) surrounding the use and motivation of 
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hormonal contraception particularly in the active duty population where lost time due to 
menorrhagia, dysmenorrhea and unplanned pregnancies pose a threat to mission readiness. 
Generalizability 
The study results may not be generalizable beyond the active duty Army. It has been 
documented that rates of contraceptive use differ between military branch in addition contributing 
factors such as operational environment, length of training and deployment may impact rates and 
type of contraceptive use. Trends in contraceptive use may resemble national trends within 
civilian populations although the Army may have higher rates of use given the healthy population 
where by contraindications are otherwise screened out during entry processing. In addition, 
TRICARE provides complete coverage of hormonal contraceptive potentially increased access to 
contraceptives compared to their civilian counterparts during the same timeframe.  
Conclusion 
To date, research surrounding hormonal contractive use has been limited to select 
populations, small samples and incomplete capture of all available contraceptive options. 
Temporal changes in contraceptive availability, changes in demographics of servicewomen, and 
changes in frequency and location of deployments contribute to the increase use in alternative 
contraceptive methods. Preference for particular contraceptive methods varied by key 
demographics where by older, married women had higher rates of IUD use and young women 
had increased use of implant and injection. Rates of use during basic training were low, and 
although rates of use remained relatively stable between U.S. home station and deployment, 
women were more likely to start and change their method while stationed in the U.S. These 
results provide data for health care planning, and hypothesis generation for future analysis 
regarding contraceptive use within the Army especially if sub-groups are identified to be at high 
risk for methods change or non-use.  The timing of this research is relevant to establish a baseline 
for future plans of gender neutral standards and gender integration in combat positions. 
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Human Subjects Protection 
The TAIHOD database was created in 1994 in order to understand risk factors for injury 
within the active duty Army population. All active duty army soldiers are included in the database 
without database specific written consent. Study personnel are trained in privacy protocols and 
electronic study database will be stored with a nonmilitary study identification number on a 
secure server that is password protected. There are no known potential risks to participants, 
except for accidental breach of confidentiality which is unlikely to occur. Additionally there is no 
known benefit to participating in the study except for advancing science in research involving 
servicewomen. This study was approved by the Institutional Review Boards of the United States 
Army Research Institute of Environmental Medicine and the University of Massachusetts 
Amherst. 
Permission to Access Data 
Permission to access data was granted by the United States Army Research Institute for 
Environmental Medicine Military Performance Division Chief  Edward J. Zambraski, Ph.D. and 
TAIHOD director  MAJ Owen Hill Ph.D. MPAS, following IRB approval by USARIEM and the 
University of Massachusetts Amherst. 
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CHAPTER 2 
 
HORMONAL CONTRACEPTIVE USE AND ACL INJURY  
 
Introduction 
Significance of Musculoskeletal Injuries in Active Duty Soldiers 
Compared to their civilian counterparts, active duty soldiers are at particularly increased 
risk for injury due to high physical demands in occupational and fitness training (Sulsky, Mundt, 
Bigelow, & Amoroso, 2002). Service members are more physically active as compared to the 
general population, and may be required to work extended shifts in difficult environments, 
especially during basic training and deployment. Injuries are the leading cause of hospitalization, 
disability outpatient visits, and manpower loss in the military compared to all other causes of 
morbidity (Tiesman, Peek-Asa, Zwerling, Sprince, & Amoroso, 2007; Sulsky et al., 2002). For 
the past two decades, musculoskeletal injuries have contributed significantly to disability 
discharge from the Army (Sulsky et al., 2002). Between 1981 and 2005, rates of disability 
discharge due to musculoskeletal injury increased around 8 fold for men and 15 fold for women 
(N. S. Bell, Schwartz, Harford, Hollander, & Amoroso, 2008). 
Women’s participation in the military has increased over the past few decades and 
currently women comprise about 15% of the Army’s active duty force (Department of Defense, 
2009).  Between 1997 and 2003, there were 4,480 female ACL injuries documented as a sprain or 
strain of the cruciate ligament (ICD-9 844.2) and 3,540 injuries documented as an old disruption 
of ACL (ICD-9 717.83) resulting in about 640 incident ACL injuries involving women in the 
military per year (Owens, Mountcastle, Dunn, DeBerardino, & Taylor, 2007). Despite conflicting 
evidence surrounding the etiology for gender differences of musculoskeletal injury in service 
members, disability discharge rates due to musculoskeletal injury in women are twice as high as 
those in men (N. S. Bell et al., 2008). 
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Knee Injuries and the Significance of ACL Injuries 
Knee injuries represent one of the most common musculoskeletal injuries (Tiesman et al., 
2007; Sulsky et al., 2002). Knee injuries often involve multi-structural damage and may 
compromise the four stabilizing and surrounding ligaments including the anterior cruciate 
ligament (ACL)(American Orthopaedic Society for Sports Medicine, 2007). Although ACL 
injuries are acute and traumatic in nature, the short and long-term implications for correction, 
recovery and subsequent injury warrant attention among highly active populations. Servicemen 
and women experience ACL injuries at rates ten times higher than the general population (Owens 
et al., 2007).  
Risk Factors for ACL Injury 
In the general population, risk for ACL injury is affected by non-physiological factors 
like skill level, shoe type, use of ankle brace/tape, and playing surfaces (Murphy, Connolly, & 
Beynnon, 2003); and physiological factors including body mass index (BMI), small femoral 
notch width and joint laxity (Uhorchak et al., 2003). To date, limited examination of ACL injury 
in the Army has identified risk factors including history of knee injury, junior enlisted rank, low 
fitness test scores, less than college education (Sulsky et al., 2002; N. S. Bell et al., 2008). Among 
female soldiers soft tissue knee injuries are inversely associated with age with the highest rates 
occurring among women under 20 years old (Hill et al., 2012). 
High BMI, joint laxity, Q-angle, femoral notch width and low fitness test scores have 
been proposed to explain the differential injury rates between men and women. A study by Bell 
and colleagues found that the gender differences in injury rates were not significantly different 
after controlling for fitness level (N. S. Bell, Mangione, Hemenway, Amoroso, & Jones, 2000). 
However, given the increased rates of injury observed among female athletes following puberty, 
endogenous hormone levels that fluctuate during the menstrual cycle and exogenous hormonal 
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contraceptive use have been suggested as possible factors that may impact joint laxity and other 
properties of musculoskeletal tissue. 
The Role of Endogenous and Exogenous Hormones 
Evidence suggests that hormonal fluctuations during the menstrual cycle may impact risk 
for ACL injury directly or indirectly by altering physiological properties of the knee and lower 
extremity. Estrogen receptors have been identified on muscle and ligament tissue surrounding the 
knee and changes in muscle stiffness and joint laxity throughout the menstrual cycle have been 
noted (Hewett, Zazulak, & Myer, 2007). Studies have suggested that hormonal contraceptives 
may decrease risk for ACL injury by attenuating endogenous hormonal surges (D. R. Bell et al., 
2012; Ruedl et al., 2009).  Given the widespread use of contraception among servicewomen 
further evaluation is warranted to characterize contraceptive users and better understand the 
injury mechanisms. 
Physiology of Hormonal Contraceptives and ACL Injury 
Gender Differences in ACL Injury Rates 
Over the past few decades, sex hormone profiles have been suggested as a contributor to 
the differential in lower extremity injury rates observed between men and women. Unlike 
anatomical sex differences (e.g. increased Q-angle among women due to a wider pelvis), 
hormonal contraceptive use is potentially modifiable. A link between endogenous hormones and 
ACL injury has been described, which holds physiologic relevance for non-contraceptive users 
and provides a foundation for understanding the implications of contraceptive use.  
Impact of the Menstural Cycle on ACL Injury 
The pathophysiology of the menstrual cycle in healthy ovulating women is well 
understood. Four key hormones regulate the menstrual cycle including two gonadotropic 
hormones (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) produced by the 
pituitary gland, and two sex steroids (estrogen and progesterone) (Shechter & Boivin, 2010). 
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Toward the end of the follicular phase both estrogen and LH spike 5 and 10 fold respectively 
(Shechter & Boivin, 2010). Following ovulation, hormonal secretion is regulated by the corpus 
luteum where progesterone rises 8 fold and a 2 fold increase in estrogen occurs (Shechter & 
Boivin, 2010).  The presence of estrogen receptors on cells of the knee suggests a potential 
impact of estrogen on joint function. Estrogen receptors have been identified on the synoviocytes 
(cells that control fluid in joints) in the knee, fibroblasts in collagen of the ACL (Hewett, Myer, & 
Ford, 2006), and also on muscle tissue (D. R. Bell et al., 2009). Hormonal fluctuations may 
impact the ability of an individual to stabilize their knee by impacting the activation patterns 
(increased hamstring to quadriceps ratio) or reducing sagittal torques at the knee (Hewett, 2000).  
The reduced ability to control knee motion, with concurrent changes in laxity and reflexes result 
in a high risk situation particularly for the ACL. Joint laxity, in particular, has been widely 
studied and can increase risk for ACL injury by impacting hypermobility (hyperextension) and is 
more common among women (Griffin et al., 2000). 
Epidemiologic studies suggest varying levels of risk for ACL injury across the menstrual 
cycle (Slauterbeck et al., 2002; Arendt, Bershadsky & Agel, 2002; Wojtys, Huston, Boynton, 
Spindler, & Lindenfeld, 2002; Lefevre, Bohu, Klouche, Lecocq & Herman, 2013; Hewett et al., 
2006). One study found an increased risk for ACL injury during menses, three noted increased 
risk before ovulation and one noted increased risk at ovulation.  
Impact Hormonal Contraception on ACL Injury 
Hormonal contraception affects endogenous hormonal levels and changes through the 
menstrual cycle. Combined hormonal contraception (CHC) contains estrogen and progesterone 
and inhibits corpus luteum formation (Rivera, Yacobson, & Grimes, 1999).  Some CHC lead to 
consistent hormone levels throughout the month, known as monophasic, whereas other CHC 
result in changes in the hormonal levels across weeks based on the type of pills (e.g. biphasic and 
triphasic). CHC inhibits pituitary production of follicle stimulating hormone (FSH) and 
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luteinizing hormone (LH) when they would normally surge mid-cycle preventing ovulation 
(Rivera et al., 1999). Endogenous FHS and LH levels decrease within a few days of initiation of 
CHC and will start to return to pre-CHC levels soon after cessation. Progestin only methods (pill, 
injection and implant) only partially suppress ovulation. The injection also prevents the mid-cycle 
surge of LH needed for ovulation (Rivera et al., 1999). Hormonal contraception impacts 
endogenous FSH and LH which would normally surge mid-cycle, interfere with ovulation 
influencing luteal hormonal exposure, as well as provide a predictable dose of hormones.  
Prior research has evaluated serum hormone levels and joint functional movement by 
contraceptive status. Combined hormonal contraceptives appear to attenuate relaxin and 
progesterone profiles. A recent study found that crude levels of serum relaxin and progesterone 
levels in nulligravid athletes were significantly lower among hormonal contraceptives users 
compared to nonusers measured at the mid-luteal surge (Dragoo et al., 2011). Increased relaxin is 
associated with increased knee laxity, due to diminished collagen tension, and may increase risk 
of ACL rupture ((Dragoo et al., 2011; Wojtys, Huston, Lindenfeld, Hewett, & Greenfield, 1998)). 
Martineau and colleagues used laboratory based measurements to assess tibiofemoral anterior-
posterior translation laxity between contraceptive users and nonusers finding significantly 
decreased laxity among contraceptive users (Martineau, Al-Jassir, Lenczner, & Burman, 2004). In 
contrast, a study by Hick-Little found no effect of hormonal contraceptives on laxity (Hicks-
Little, Thatcher, Hauth, Goldfuss, & Cordova, 2007).  
Differences in hormonal profiles between men and women may potentially play a role in 
differential risk of ACL injury. Estrogen receptors have been identified on the knee and it is 
plausible that changes in endogenous hormone may impact knee stability and injury risk. 
Hormonal contraception alters the natural level and fluctuation of endogenous hormones and 
therefore may also impact risk for ACL injury. Prior studies have shown hormone serum and 
biomechanical differences by contraceptive use. . Combined hormonal contraception more 
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completely suppresses ovulation and could potentially result in greater stability of cyclic 
variations, though, progestin only methods partially suppress surges and could offer some benefit. 
Hormonal contraceptive use could be a potentially important modifiable risk factor for ACL 
injury risk; however limited research to date warrants additional investigation. 
Epidemiology of Hormonal Contraceptives and ACL Injury 
Five epidemiological studies to date have evaluated the association between hormonal 
contraceptives and ACL injury, which have included a total of 68,150 participants and 17,464 
ACL injuries (Agel, Bershadsky, & Arendt, 2006; Liederbach, Dilgen, & Rose, 2008; Ruedl et 
al., 2009; Rahr-Wagner, Thillemann, Mehnert, Pedersen & Lind, 2014; Gray, Gugala, & 
Baillargeon, 2016). Two of these studies were prospective in design, with self-report 
contraceptive exposure, capturing 55 ACL injuries among 3,333 athletes (Agel et al., 2006; 
Liederbach et al., 2008), and three were case-control. The first case-control study matched cases 
to controls (1:1) and collected self-report contraceptive use among186 skiers, while the latter two 
utilized medical billing codes to identify ACL surgical repair and contraceptive pick up among 
47,315 controls and 17,316 cases in the general population (Ruedl et al., 2009; Rahr-Wagner et 
al., 2014; Gray et al., 2016). In addition, two systematic reviews published in 2017 both identified 
7 studies that examined the association between hormonal contraceptive use and ACL injury, two 
of which were case series and not included in our review (Herzberg, Motu’apuaka, Lambert, Fu, 
Brady & Guise, 2017; Samuelson, Balk, Sevetson, Fleming, 2017).  
In the largest prospective study of hormonal contraceptive use and ACL risk conducted to 
date, Agel et al. followed a cohort of 3,150 female basketball and soccer collegiate athletes over 
two seasons (Agel et al., 2006). Hormonal contraceptive status was collected by self-report of 
athletes to their athletic trainers at the beginning and end of the season and users were categorized 
as monophasic, triphasic or other (injectable, unidentified contraceptive or known change of 
contraceptives). Incident ACL injuries occurring by a noncontact mechanism were reported to the 
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research team by athletic trainers and confirmed with a clinical exam or diagnostic imaging. The 
rate of incident ACL injuries was analyzed by season (2000 and 2001) and by sport (basketball 
and soccer).  
Compared to women who did not use hormonal contraceptives, women who used 
contraceptives had similar risk for ACL injury in unadjusted estimates for 2000 (OR 0.95, 95% 
CI 0.38-2.35) and for 2001 (OR 1.02, 95% CI 0.31-3.43)(Agel et al., 2006). Additionally, the 
authors found no statistically significant association between hormonal contraceptives and ACL 
injury in analyses stratified according to basketball players (OR 1.14, 95% CI 0.55-2.36) or 
soccer players (OR 1.17, 95% CI 0.36-3.85). Despite having a relatively large overall number of 
participants, the small number of ACL injuries observed (n=45) resulted in low statistical power, 
and complicated interpretation of the null findings. In addition, the authors did not evaluate other 
types of hormonal contraceptives (e.g., injectable, patch, ring) and failed to consider prior lower 
extremity injury and BMI. Withstanding these limitations, Agel and colleagues were the first to 
publish on the association between contraceptive use and ACL injury and provide a foundation 
for the studies that followed. 
Liederbach et al. assessed ACL injury among 183 female ballet and modern dancers over 
a 5 year period, capturing a total of 10 ACL tears (Liederbach et al., 2008). Certified athletic 
trainers conducted annual screenings during the study period to assess contraceptive use. 
Standardized questionnaires were used to assess ACL injuries and were categorized as either 
partial or complete rupture of the ligament confirmed by diagnostic imaging. In an unadjusted 
comparison, women who used hormonal contraceptives had a 68% decrease in risk of ACL injury 
as compared to nonusers, though results were not statistically significant (calculated OR 0.32, 
95% CI 0.09-1.16). This study, similar to Agel et al., was limited in power to adequately assess 
the association between hormonal contraceptives and ACL injury and was limited to oral 
contraceptive use. Although there was no significant association between hormonal contraceptive 
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use and ACL injury, the calculated OR has a magnitude of protection consistent with Möller-
Nielsen and Hammar, encouraging larger future studies to continue to assess the association. 
Ruedl et al. (2009), utilized a case-control study to assess oral contraceptive use and risk 
of ACL injury among 186 Austrian recreational skiers. Cases (n=93) included women treated for 
noncontact ACL injuries with MRI confirmed diagnosis at a local clinic. Controls (n=93) were 
skiers selected on five different days at the slopes and were age matched to cases. Oral 
contraceptive use was obtained on a questionnaire and dichotomized as use and nonuse. There 
was no difference in risk of ACL injury between those who used oral contraceptives and those 
who did not (unadjusted OR 0.95, 95% CI 0.52-1.74). The statistical power of this study was 
limited by the small sample size utilized, as well as by likely misclassification related to use of 
self-report for oral contraceptive status. Though limited in power, their results, utilizing a 
different study design, support the conclusion of the two prior studies. Ruedl and colleagues 
contributed to prior literature by readdressing the relationship between hormonal contraceptive 
use, menstrual cycle timing and ACL injury.  
In the first study to consider ACL injury resulting in operative repair, Rahr-Wanger and 
colleagues (2014) identified women with cases of operatively treated ACL injury (n=4,497) in the 
Danish Knee Ligament Reconstruction Registry between 2005 and 2011 (Rahr-Wagner et al., 
2014). Two population controls (n=8,858) per case were selected using risk-set sampling from the 
Danish Civil Registration system and were matched to cases on age. Contraception use was 
classified as ever/never and was determined from pharmacy records; use was defined as picking 
up at least 1 prescription for oral contraception during the study period. The authors additionally 
classified women as new users (i.e., first prescription in the last year), recent users (i.e., 
prescription >1 year before the index date), and long term users (i.e., prescription in the last 1 to 5 
years before the index date). During the 5 year period, 45% of women ever used oral 
contraceptives. Ever contraceptive users had 18% decreased risk of ACL injury needing surgical 
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repair (RR 0.82, 95% 0.75-0.90) with similar findings among long term and recent users. There 
was no association between new use and ACL surgical repair. Additionally, they found deceased 
risk of ACL surgical repair among any duration of use up to four years with the greatest reduction 
in risk at 3 years (RR 0.75, 95% 0.64-0.90) as compared to never users. There was no significant 
protection among women who used contraceptives longer than 4 years. This study adds to prior 
literature by considering duration of contraceptive use as well as ensuring the temporality of 
hormonal use prior to ACL surgery. The most notable limitation of this study is the lack of 
complete capture of incident ACL injuries resulting from the case definition (i.e., those with 
operative repaired ACL injury). Because not everyone who sustains an ACL injury will proceed 
with surgical repair, it is possible that women who opt for surgical repair may be different than 
nonsurgical counterparts (Rahr-Wagner et al., 2014). Despite this limitation, Rahr-Wagner and 
colleagues add to existing literature by considering duration of use as recent use to assess time off 
contraceptives prior to operative repair.  
In the largest published study to date, Gray and colleagues (2016) utilized the 
Clinformatics Data Mart, database of insurance claims in the United States to identify women 
who underwent ACL reconstruction (n=12,819) as cases of ACL injury over a 11 year timeframe. 
They matched controls to cases in a 3:1 ratio based on index date, age and region. The average 
age of women undergoing repairs was 24 which they noted was 3-4 years younger than a prior 
report from Maletis and colleagues suggested (Maletis, Granan, Inacio, Funahashi, Engebretsen, 
2011). Hormonal contraception was measured as any oral contraceptive use in the 12 months 
prior to the index date. There was no difference in operative ACL among ever users of any 
hormonal contraception OR 0.98 (95% CI 0.94-1.04), though women with use less than 90 days 
were 11% less likely to need surgical repair (OR 0.89, 95% CI 0.81-0.99). The authors found that 
young women aged 15-19 using oral contraceptives were 18% less likely to have ACL surgery 
(OR 0.82, 95% CI 0.75-0.91) as compared to women aged 25-29 and 30-35 were 15% more 
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likely (OR 1.15, 95% CI 1.02-1.3 and OR, 1.16 95% CI 1.04-1.31 respectively). This study 
excluded all other types of hormonal contraception as well as women diagnosed with Turner 
Syndrome, follicular cyst, acquired atrophy of ovary or fallopian tube, benign or malignant 
neoplasm of ovary, which prior studies have not done. They also considered diabetes, asthma and 
any use of oral, injectable or inhaled steroids as covariates. A notable limitation is that this study 
did not consider women who sustained an ACL injury but did not have surgical repair. Gray and 
colleagues were the first to find a statistically significant association between hormonal 
contraception and operative repair of the ACL among recent users and among young (ages 15-19) 
ever users which suggest there could be underlying difference in both hormonal fluctuation, 
choice of exogenous hormone and injury risk by age. Although their study was the largest to date, 
the use of surgical repair as a proxy for incident injury leads to incomplete capture of ACL cases 
and future studies should aim to completely capture incident injury on a similarly large scale. 
In 2017, two systematic analysis were published which summarized the studies to date 
including those discussed in detail above with the addition of Liederbach et al. (2008), which was 
not included in either review (Herzberg, Motu’apuaka, Lambert, Fu, Brady & Guise, 2017; 
Samuelson, Balk, Sevetson, Fleming, 2017). These literature reviews also included two case 
series (Lefevre, et. al, 2013; Wojtys, et. al, 2002).and one small cohort (n=83) (Arendt, et al., 
2002) focused on the timing of ACL injury during the menstrual cycle, enrolling only women 
with ACL injuries. Without a comparison, uninjured, group we are unable to assess the direct 
impact of contraception on ACL injury in these studies; those studies with noninjured comparison 
groups were excluded from the review above. The systematic reviews suggest that, taken 
together, recent literature indicates a protective effect of hormonal contractive use with up to a 
20% reduction in ACL injury. However, the authors of these reviews noted that although the 
literature has increased in number, the overall strength of the studies still remains poor due to 
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limited prospective capture, focus only on oral contraceptive pills, lack of consideration of 
appropriate confounders and sensitivity analysis.  
Samuelson and colleagues (2017) at Brown also conducted a review of literature 
surrounding timing of menstrual cycle, including five studies published between 2002 and 2013. 
Although these results are inconclusive due to inconsistent classification of menstrual phase 
across studies, it is important to note there was no risk of ACL injury associated with the luteal 
phase (among contraceptive users or nonusers). Herzberg and colleagues (2017) at Oregon Health 
& Science University reported similar conclusions regarding menstrual phase timing. They 
additionally considered knee laxity across menstrual phase in six of twelve published studies, 
noting a greater laxity at ovulation compared to the follicular phase without a difference between 
follicular and luteal phases (Herzberg et al., 2017; Samuelson et al., 2017). In summary, previous 
studies of the relationship between hormonal contraceptive use and risk of ACL injury have been 
limited. The only three studies, two cohorts and one case-control, to consider incident ACL injury 
found no significant association (Agel et al., 2006; Liederbach et al., 2008; Ruedl et al., 2009).  
The two most recent studies, both case-control in design, suggest there is a significant 
reduction in ACL surgical repair, as a proxy for ACL injury, among hormonal contraceptive users 
(Rahr-Wanger et al., 2014; Gray et al., 2016).The two most recent studies considered important 
covariates in their analysis including age, BMI, NSAID use, ethnicity, prior injury and pregnancy. 
Main limitations have included small sample size, incomplete ACL injury captures (e.g., 
inclusion of only those with surgical repair or only without surgical repair), assessment of OC use 
and issues related to establishing temporal ordering of OC use and ACL injury. Thus, while it has 
been suggested that contraceptive use may reduce risk of ACL injury by up to 20%, limitations in 
prior studies leave uncertainty regarding the association. Moreover, to our knowledge, no studies 
to date have assessed dose or contraceptive type other than the pill and only two have considered 
duration with regard to risk of ACL injury. These factors are likely to have varying impacts on 
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endogenous menstrual response, and the insufficient assessment of dose, duration and type of 
hormonal contraception on ACL injury risk is an important research gap. Because of the limited 
number of studies of the relationship between contraceptive use and risk of ACL injury, and the 
limitations of those previous epidemiologic studies, further research is warranted. 
Knee injuries have contributed to a significant proportion of disability discharge from the 
Army over the past few decades (Sulsky et al., 2002; Hauret, Jones, Bullock, & Canham-
Chervak, 2010). Women are a growing segment of the military population and have increasingly 
become involved in physically demanding jobs (Department of Defense, 2009). Between 1997 
and 2003 there were over 4,000 ACL injuries among servicewomen alone (Owens et al., 2007). 
Women appear to be at increased risk for ACL as well as other knee injuries (N. S. Bell et al., 
2008). Known modifiable risk factors for knee injury include fitness and BMI, however the 
gender inequality in injury risk is not well understood. 
It has been suggested that hormonal contraceptive use may decrease risk of ACL injury 
by attenuating endogenous hormonal surges throughout the menstrual cycle which may impact 
neuromuscular strength, reaction and joint laxity (Hewett, 2000). Previous research has identified 
hormone receptors on muscles and ligaments which respond to endogenous hormone surges 
decreasing strength, and overall laxity (Renstrom et al., 2008). These characteristics of the knee 
are important predictors, and often components, of ACL injury. 
Because of limitations of existing epidemiological studies evaluating the relationship 
between hormonal contraceptive use and risk of ACL injury, the relationship remains uncertain. 
Between 2006 and 2009, two prospective cohorts and one case-control study examined the 
association in dancers, basketball players, soccer players and skiers (Agel et al., 2006; Liederbach 
et al., 2008; Ruedl et al., 2009). These studies found no statistically significant association 
between hormonal contraceptive use and ACL injury, though they were limited in sample size 
and dichotomized self-report exposure assessment. Two case control studies were published in 
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the last 3 years using operative repair of the ACL as a proxy for injury found that contraceptives 
may decrease risk by 20% (Rahr-Wagner et al., 2014; Gray et al., 2016).  No studies have 
included all contraceptive types or dose of contraceptive use and ACL injury in the military 
population. To address this research gap, we evaluated the relationship between type, dose, and 
duration of hormonal contraceptive use and risk of ACL injury in the active duty Army 
population over a ten year period between January 2002 and December 2011. 
Aim and Hypotheses 
Specific Aim: To evaluate the association between hormonal contraceptive use and risk 
of ACL injury among active duty Army servicewomen. Hypothesis 1: Compared to non-users, 
hormonal contraceptive users will have lower risk of ACL injury. Hypothesis 2: Compared to 
non-users, combined hormonal contraceptive users will have the lowest risk of ACL injury 
followed by progestin only users. Hypothesis 3: Compared to non-users, increasing duration of 
hormonal contraceptive use will have an inverse relationship with ACL injury.  
Methods 
Study Design and Population 
The study population consists of servicewomen between the ages of 17 and 45 who 
served at least two months on active duty between January 1st, 2002 and December 31st, 2011 
using the TAIHOD. The TAIHOD was created in 1994 with the aim to study injuries among 
female soldiers, though the database captures servicemen and women. The database prospectively 
links administrative, clinical, pharmaceutical, occupational and health behavior data for all 
soldiers who have been on active duty. The TAIHOD currently contains data on over 5 million 
soldiers with active service and outpatient clinical records as far back as 1997. For the current 
study, the start date of January 1st, 2002 was selected as it marks the onset of electronic 
pharmacy record capture from the PDTS, which is integrated into the TAIHOD to determine 
hormonal contraceptive use. This timeframe captures Operation Enduring Freedom and Operation 
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Iraqi Freedom (OEF/OIF), which allows for evaluation of changes in contraceptive preference 
and use in austere environments as well as changes in number and frequency of deployments. 
Among active duty Army soldiers between 2002 and 2011, there were a total of 207,777 
women. In any given year during this 10 year period, about 82,000 women were on active duty; 
servicewomen comprised between 13.6-15.8% of the active duty Army over the ten-year study 
period. Two thirds of the women on active duty between 2002 and 2011 were new accessions, 
entering the cohort in 2002 or later. The average age at entry into the cohort was 24. Most women 
had high school education or equivalent at entry. Less than one quarter of women had a rank of 
senior enlisted or officer at entry. At entry, 30% were overweight or obese. More than half were 
ever deployed at least once during the cohort and one quarter had a delivery during the cohort. 
Half had a documented knee injury during the cohort, 30% had a back injury and 15% an ankle. 
Most women ever used NSAIDs during the cohort. 
Exclusion 
For the purpose of the current study, women with only one record in the DMDC were 
dropped due to the insufficient observation time to capture and quantify hormonal contraceptive 
use, changes in duty station and other undetermined cause for military discharge that make these 
women not generalizable to the active duty women who serve for longer periods of time. In order 
to restrict consideration to pre- and not peri-menopausal women, women were censored from the 
analysis at the age of 46. Thus, women who entered the cohort at age 46 did not contribute any 
observation time to the study; however, women who turned 46 during the study timeframe 
contributed person time up until censoring at age 46, with subsequent person time dropped. 
Participants who were missing age, education, marital status, race or ethnicity from the DMDC 
were excluded. From this population, we further excluded women who had medical record 
documentation of a hysterectomy, oophorectomy, clinically diagnosed menopause, or used 
hormone replacement therapy as these women likely have different comorbidities that may 
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impact their use of hormonal contraceptives (Appendix A). In addition, women who experienced 
one of these events during the study cohort were dropped at the event date and person time 
following the event was also dropped. Women with greater than 120 pregnancy visits during the 
study cohort were also excluded. These women compromise a group of either implausible 
medical records or high risk pregnancies that are likely not generalizable. The number of women 
and person years excluded and dropped are shown in Table 7. Although rare, women with any 
lower extremity amputation were excluded or dropped as their risk for ACL injury is expected to 
be vastly different compared to other servicewomen. Women with known ACL injury prior to 
2002, contralateral or recurrent injury, were dropped to identify incident ever ACL injuries. The 
number of women and person years excluded and dropped are shown in Table 7. 
Exposure Assessment: Hormonal Contraception 
Hormonal contraceptive use was assessed through pharmacy data recorded in the PDTS 
within the Medical Data Repository. The PDTS is a complete database capturing all prescription 
pick-ups at Military Treatment Facilities, TRICARE pharmacy networks, and mail orders 
(Department of Defense, 2009; The Department of Defense Pharmacoeconomic Center, 2011). 
Pharmacy records contain information on: therapeutic class, product name, type of hormonal 
contraceptive, dosage, days’ supply, quantity and date pick up. TRICARE covers hormonal 
contraceptives at no cost to soldiers (Enewold et al., 2010). Therapeutic class codes ‘681200, 
contraceptives’ and ‘683200, progestins’ were used to identify hormonal contraception. 
Prescriptions recorded with a dispense quantity equal to zero were considered as requested but 
not picked up. Prescriptions for HRT or treatment for amenorrhea and anovulation were not 
included in the analysis as hormonal exposure.   
The PDTS dataset contains information on the date, quantity and contraceptive type 
dispensed. Product type other than: pill, patch, injectable, implant, vaginal ring were eliminated. 
Exposure was further categorized by type of contraceptive to evaluate differences in use of 
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combined hormonal contraceptive versus progestin only. Combined hormonal contraceptives 
included monophasic, biphasic and triphasic oral contraceptives, Ortho-Evra (birth control patch), 
and Nuvaring. Progestin only contraceptives include progestin only pill, Depo-Provera 
(injection), Mirena (intrauterine device) and implants (including: Noroplant, Implanon and 
Nexplaon). Timing and duration of use was determined from start and stop dates were calculated 
as follows: start date equals date of pick up plus one day and the end date is equal to the start date 
plus the quantity provided.  
For consistency with prior literature, we initially dichotomized hormonal contraceptive 
use as ever versus never user. Taking advantage of the extensive information included in the 
TAIHOD, we additionally considered use as ‘never’, ‘past’ and ‘current’, as well as contraceptive 
type (pills type, patch, ring, injection, IUD and implant). These methods were collapsed into 
combined hormonal contraceptive and progestin only. We also looked at duration of any 
contraceptive use as defined by short (<90 days), medium 90-365 and long 365+. Prior studies 
have identified 90 days as an appropriate cut point for short use as women are often encouraged 
to trial a new method and 97% of those that use for 3 months will continue using in month 4 
(Rosenberg, M.J. & Waughm, M.S., 1988).  
To examine the impact of never versus current use, the variable never’, ‘past’ and 
‘current’, was combined with both type and duration. Prior studies have not considered dose of 
contraceptives which is equivalent to the duration of use by type of use. To examine dose we 
created a 10 level mutually exclusive variable that incorporates both type of method and duration 
of use. Our final categorization of contraceptive use evaluated time since stopping use of any 
contraceptive method (Table 10). 
Validity of Exposure 
Hormonal contraceptive pharmacy records have not been validated in the TAIHOD. 
However, previous research have suggested that pharmacy records are a valid source of 
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information regarding use, duration and timing of contraceptives when compared to self-report 
(which is the most frequently utilized method of exposure assessment).  Discordance between 
pharmacy records and self-report may result from inaccurate self-reporting, or when prescriptions 
are filled but not used. Pharmacy records have also been found to be a more accurate source of 
information than self-report for type of oral contraceptives (high dose, low dose and progestin 
only pill), with correlation coefficients between self-report and pharmacy records ranging from 
0.84-0.93 (Norell et al., 1998). Use of pharmacy records for assessment of duration of use 
requires assuming that any prescription dispensed was used for the entire days’ supply as directed 
by the pharmacy.  
Outcome Assessment: ACL Injury 
ACL injuries were the outcome of interest and were identified by ICD-9 code 844.2 in 
medical records. This code identifies ‘sprain of cruciate ligament of the knee’. The first date of 
service for this ICD-9 code was selected to identify incident ACL cases (Table 8). Identification 
of ACL tears through medical records is considered to be the gold standard. It is important to note 
that this ICD 9 code also includes posterior cruciate ligament (PCL) tears. However, previous 
studies have continued to utilize this ICD-9 code for determination of ACL injury with 
confidence as PCL tears are rare. PCL tears occur from abrupt traumatic front end forces to the 
lower leg including a knee hitting a dashboard in a motor vehicle accident.  
Records were also reviewed for CPT codes indicating diagnostic imagining (X-ray, 
magnetic resonance imaging-MRI). Procedure codes (81.43) triad of knee and (81.45) repair of 
cruciate ligament were abstracted to identify women who had surgical correction.  Clinical 
encounter data for women who had been on active duty prior to 2002 was reviewed to exclude 
prior ACL injury. Because history of ACL injury is an important risk factor for recurrent injury, 
and has been most recently reported to increase risk 6 fold compared to primary injury 
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(Paterno.,M.V., Rauh, M.J., Schmitt, L.C., Ford, K.R., & Hewett, T.E., 2014), only first 
documented ACL injuries were considered in the TAIHOD.  
Covariate Assessment 
Demographic data including age, race, ethnicity, education, marital status, grade and 
length of service were extracted from the monthly DMDC data repository. When a service 
member joins the military without any previous military they are considered to be a new 
accession. For new accessions, length of service represents any time on active duty in the study 
cohort between 2002 and 2011. For women with active duty time prior to 2002, length of service 
a sum of all time on active duty prior to and including the cohort timeframe  Ever attendance to 
BCT was identified from training records, however, dates of basic combat training (BCT) were 
determined as discussed above. Deployment records and overseas station dates and location were 
merged in with DMDC records. A single measurement of body mass index (BMI), as measured at 
accession, was also merged with the demographic data.  Diagnostic and medical procedure billing 
codes from the time a woman entered active duty were available and utilized to identify lower 
extremity injury and delivery (Appendix A). Records for women who served on active duty prior 
to 2002 were included to capture the number of deliveries and lower body injuries prior to the 
cohort. Parity was determined by the number of dependents, marital status, age and delivery 
during the study cohort. Women with a known delivery during the study are automatically parous. 
Women without any documented deliveries, but were married with 2 or more dependents were 
also considered parous. Women who were, single with no dependents were considered 
nulliparous. Ever use of prescription NSAIDs and count were also determined from pharmacy 
records. 
Univariate Analysis 
We reported the number, percent  and total active duty person years in TAIHOD and the 
number and percent of those who are excluded due to missing records, age over 45, previous 
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hysterectomy, oophorectomy, menopause, hormonal therapy, lower extremity amputation and 
previous ACL injury (Table 7). The percent distribution of ACL injuries as well as use of 
diagnostic technology and clinical interventions were presented (Table 8).  
Bivariate Analysis 
The association between entry covariates and ACL injury was assessed through chi-
square tests and results of the cross tabulation were reported (Table 9). Percent and distribution of 
hormonal contraceptive exposure by ACL injury are presented in Table 10 across all 
contraceptive categorizations. Unadjusted relative risks and 95% confidence intervals were 
calculated to compare hormonal contraceptive users with non-users as the reference group, with 
regard to ACL injury (Table 10). 
Multivariable Analysis 
The relationship between hormonal contraceptive use and ACL injury was modeled using 
survival analysis to estimate hazard ratios and 95% confidence intervals (Table 10). Nine 
categorizations of contraceptive exposure were considered in this analysis. Potential confounders 
were identified as being significantly related to both contraceptive use and ACL injury. The only 
confounder consistently identified by prior literature included age which was automatically 
retained in the final model. Likelihood ratio tests comparing models with these covariates to the 
hormonal contraceptive ever/never model were conducted and models that remained significant 
(p<0.05) were retained for continued step-wise model building. The variables for the final model 
of hormonal contraceptive ever/never were then applied to the eight remaining categorizations of 
contraceptive exposure. 
Three models were considered in the final analysis (Table 10) including: 1) unadjusted, 
2) age adjusted and, 3) final adjusted model. A sensitivity analysis considered only new 
accessions during the study cohort to capture the full spectrum of career events servicewomen 
face to ensure inclusion of basic training, advanced individual training and deployment where 
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both contraceptive use and risk for ACL injury may differ from permanent duty station (Table 
11).   
Results 
Final Study Sample 
Exclusions are detailed in Table 7. Of the 207,777 participants and 757,610 person years 
of total observation, the most common reason for exclusion was due to missing records 
(n=6,347). Over one third of those excluded (n=3,544) only had one month record in DMDC. An 
additional 2,803 women were missing age, education, marital status, race or ethnicity. An 
additional one percent of women were excluded from the study due to being age 46 or older at 
entry to the cohort or to the Army. Less than one percent of the study population was excluded 
due to a medical reason. A total of 80 women were excluded from the study due to lower 
extremity amputation and an additional 1,501 women were excluded due to known prior ACL 
injury before 2002. Half of the women excluded at entry and the majority of women dropped 
during the study time frame had service prior to 2002 (Table 7). 
ACL Injuries 
We identified 195,815 eligible women in the TAIHOD between 2002 and 2011 resulting 
in 703,499 person years (Table 7). Of these women, 2,253 experienced an incident ACL injury 
representing a rate of 3.20 per 1,000 person years among the entire cohort and a rate of 3.28 per 
1,000 person years among new accessions (Table 8). Less than 6% of incident ACL injury had a 
knee x-ray and less than 10% had an MRI around the time of injury. Only 15% of women would 
go on to have their ACL surgically repaired while in the Army. 
Correlates of ACL Injury 
Compared to women who did not have an ACL injury, women who did had 10% higher 
probability of service prior to 2002 (44.43% vs. 34.74%). These women were on average one 
year older, had slightly higher education, marital status and rank. Women with an ACL injury 
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were more likely to be African American, as well as with a prior knee, back, hip, ankle or leg 
injury. Women with incident ACL injury had 6% higher likelihood of being overweight or obese 
(36%) compared to women without ACL injury (30%) at entry to the Army (Table 9). 
Hormonal Contraceptive Use and ACL Injury: Ever Use 
Ever users of hormonal contraceptive had 14% decreased likelihood of ACL injury as 
compared to never users (HR 0.86, 95% CI 0.79-0.93) (Table 10). After adjusting for age, knee 
(never, past current injury), NSAID use (never, past or current), deployment (never, past or 
current), pregnancy (never, past current), race/ethnicity, back or hip injury (never, past current) 
and new accession,   the overall protection of hormonal contraceptives was eliminated (HR 0.95, 
95% CI 0.86-1.04). However, current users continued to have a 15% decrease in incident ACL 
injury (HR 0.85 95% CI 0.76-0.94). 
Hormonal Contraceptive Use and ACL Injury: Type of Use 
The seasonal contraceptive pill was associated with the lowest estimated hazard (HR 
0.44, 95% CI 0.20-0.97) among evaluated methods. A nonsignificant increased risk was observed 
for the implant (HR 1.22, 95% CI 0.72-2.08) in the unadjusted model. In the analyses comparing 
methods grouped by type, progestin only users in their career had the lowest risk of ACL injury 
(HR 0.78, 95% CI 0.65-0.94) compared with 0.88 for users of a combined hormonal 
contraception (HR 0.88, 95%CI: 0.80-0.96) and 0.84 for users of both progestin only and 
combined contraceptive methods (HR 0.84, 95% CI 0.74-0.97) compared with non-users. A 
similar result was observed in analysis considering past use however, current users who had ever 
used either method had the most protection.  
Hormonal Contraceptive Use and ACL Injury: Duration of Use 
The longer women used any type of hormonal contraceptive the more protected they 
were against ACL injury (Table 10). As length of contraception use increased among combined 
only user, risk for ACL injury decreased. However, the opposite was true for progestin only users 
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who experienced the lowest risk in the short term use group. These results remained consistent 
after controlling for age and patterns remained similar while looking among only new accessions 
(Table 11). Among new accession, increasing time since last use appeared to have increasing 
trend of risk for ACL injury, though again none of these results were statistically significant. 
In all models, with the exception of new accessions, women who recently stopped 
hormonal contraception in the past 90 days had an increased likelihood of ACL injury, compared 
to never users. 
Discussion 
Summary of Findings 
Of the 195,815 women included in the cohort, 2,253 experienced an incident ACL injury 
resulting in a rate of 3.20 per 1,000 per years among the entire cohort and a rate of 3.28 per 1,000 
among new accessions. Few had documented imaging or surgical repair. Women with ACL 
injury were on average one year older, had higher level of education and higher rank. Women 
with an ACL injury were more likely to have a prior knee, back, hip, ankle or leg injury and were 
6% more likely to be overweight or obese at entry to the Army.  
Ever users of hormonal contraceptive had 14% decreased likelihood of ACL injury as 
compared to never users in the unadjusted model, however in the final model the protection was 
attenuated. In the final model, current users saw a 15% decreased risk in ACL injury. These 
trends remained similar in the sensitivity analysis among new accessions, however, they were no 
long statistically significant.  
Progestin only users had the lowest overall risk as a class with greater than 20% 
reduction in ACL injury the full unadjusted model and final model among new accessions only as 
compared to never users. Among all servicewomen, those who used the depo injection were 
significantly less likely to have an ACL injury with similar, nonsignificant, trends among IUD 
and Implant users. It is important to note pill and patch users had 13% and 45%, respectively, 
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reduced risk of ACL injury in the final model. When considering among new accessions only, 
IUD users had the lowest risk, with 40% reduction as compared to never users. 
With regards to timing of contraceptive use, as duration of used increased, overall, the 
hazards decreased. Recent starters on any contraception saw no benefit or consequence from their 
short term use. However, among all models, with the exception of that limited to new accessions, 
women who recently stopped using contraceptives of any type in the last 90 days were more 
likely to have an ACL injury than never users.   
Consistency with Prior Literature 
Rates of ACL injury in women between 2002 and 2011 were slightly higher than reported 
by Owens and colleagues between 1997 and 2003 (3.2 versus 2.95 per 1,000 person years 
respectfully) (Owens et al., 2007). Consistent with our findings, previous studies also identified 
higher BMI and prior knee injury as risk factor for ACL injury. However, previous reports in the 
Army suggest service women who are younger, junior enlisted with lower rates of college 
education have the highest risk. Our results directly conflict with these prior reports likely due to 
the inclusion of women with service prior to 2002. These women contribute to more than half of 
ACL injuries and their characteristics at entry to the study cohort (January 2002) may not be 
representative of their true characteristics at entry to the Army. 
The unadjusted hazard ratio in Table 10 suggests hormonal contraceptives may reduce 
ACL injuries by up to 14% although it does not hold true for ever users in the final adjusted 
model, current users continue to see a 15% lower hazard.  These findings are consistent with the 
recent study by Gray et al. (2016) which found an 18% reduction among 15-19 year olds and the 
study by Rahr-Wagner et al. (2014) which found an 18% decrease among ever users. In contrast 
to our findings, Gray et al. found no protective effect over all among ever users, and a 15% 
increase among women 25-35 years old. Gray et al. were the first to consider the association by 
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age groups. Differences may be explained by the instituted exclusion criteria inherent to military 
selection and our inclusion of all contraceptive types which also vary by age.  
With the exception of the contraceptive patch, we found progestin only use, as a class, as 
well as injection and IUD use had the lowest risk of ACL injury. Only one prior study has 
considered type of contraception. Gray et al. (2016) considered progestin only, monophasic and 
triphasic pills. They found a triphasic pills were 10% more likely to cause ACL surgical repair, 
although this result was not statically significant. Gray also found progestin only users were 10% 
less likely to have ACL surgical repair. We expected combined hormonal contraceptive users to 
have lower rates of ACL injury due to the direct receptors on the ACL as well as more complete 
inhibition of ovulation. However, our results compliment previous research on timing of ACL 
injury during menstrual phase suggesting increased risk of ACL injury during the follicular phase, 
when estrogen is high. There has been no associated risk with the luteal phase, when progesterone 
is relatively elevated. 
We found that increasing protection against ACL injury with increasing duration in the 
unadjusted model. However, in the final model only short, <90 days, and long, >365 days 
duration of any use were both associated with 10% decrease in ACL injury. Gray et al. (2016) 
only considered use <90 or greater than and found similar results with 11% reduction in risk. 
Rahr-Wagner et al. (2014) considered duration of use in year intervals and found protection with 
all use under 4 years as compared to never users with the greatest reduction of 25% in ACL 
surgical repair in 3 years of contraceptive use. Differences in our findings again could be 
explained by difference in age, comorbidities and contraception type we considered, not reflected 
in previous research. Our results demonstrate the important of considering the use of all type of 
hormonal contraceptive as the risk for ACL injury varies widely by type.   
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Limitations 
Non-differential Misclassification of Hormonal Contraceptive Use 
Hormonal contraceptive use was determined using pharmacy records. Misclassification 
of hormonal contraceptive use based on pharmacy records will occur in a number of 
circumstances including: servicewomen who fill prescriptions for hormonal contraceptives but do 
not use them and are misclassified as users; servicewomen who have an IUD or Implant inserted 
before they joined the Army and are misclassified as non-users; servicewomen given multiple 
months of contraception coverage that was not documented in their medical records whose 
duration of use will be underestimated. Additionally, servicewomen who pay for hormonal 
contraceptives out of pocket from pharmacies not recorded in the database will be misclassified 
as non-users. We expect this misclassification to be minor due to insurance coverage for 
hormonal contraceptive by TRICARE which covers these prescriptions at no cost to active duty 
soldiers. Pharmacy records are maintained for all servicewomen by different database than where 
clinical records are maintained. Documentation of contraceptive prescription pick up would not 
be expected to differ by ACL injury and would bias results toward the null. 
Non-differential Misclassification of Continuous Use 
Due to the limitations of PDTS we are unable to identify continuous contraceptive users. 
Continuous use occurs when a woman intentionally discards the last week of inactive pills (the 
last seven pills in a normal 28 day oral contraceptive pack) and immediately starts a new cycle of 
active pills. This electively induces amenorrhea (skipping a menstrual cycle) and exposes the 
woman to additional 91 days (or 125%) exogenous hormones throughout the year compared to a 
traditional pill user. PTDS records do not indicate if a contraception method is being used 
continuously or as prescribed. It is unlikely that differential misclassification of hormonal 
contraception use occurred given the records were collected prospectively prior to ACL injury.  
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Non-differential Misclassification of ACL Injury 
Soldiers with ACL injury were identified through medical records billing using ICD-9 
codes, which have clear diagnostic criteria. It is unlikely that injured soldiers go undiagnosed due 
to the severity of symptoms associated with ACL injury. Because of the pain, swelling and 
inability to put weight on the injured leg related to ACL injury, and the high physical demands 
placed on soldiers, seeking medical treatment for the injury is likely. It is also unlikely that 
soldiers are incorrectly diagnosed as having an ACL injury. Both sources of misclassification of 
ACL injury (i.e., false negative and false positive for ACL injury) are not expected to differ 
according to hormonal contraceptive status, and would therefore tend to result in a bias toward 
the null. We expect this misclassification was minimal. It is unlikely that differential 
misclassification of ACL injury occurred given the traumatic natures of the injury and 
standardized clinical assessment.  
Selection Bias 
Given the cohort study design, and the real time capture of hormonal contraception use 
prior to the occurrence of ACL injury, selection bias is primarily a concern to the extent that 
women may have been differentially lost to follow-up based on hormonal contraceptive use and 
ACL injury. Soldiers are required to have regular medical exams, therefore the main way losses 
from the dataset may occur is due to separation from active duty. In addition, given the traumatic 
nature of ACL injuries and required medical documentation to receive disability benefits from 
occupational injuries, it is unlikely that a servicewoman would withhold medical evaluation until 
discharged from duty.  
Confounding 
We evaluated age, BMI and pregnancy as confounders that have been previously 
recognized in the literature. Education, rank (which may be a proxy for intensity of occupational 
requirements), were also considered as potential confounding factors, among others. We are 
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aware of at least three potential confounders that are not directly available through our dataset: 
BMI at time of injury, physical fitness and intensity of unit training. BMI at the time of injury is 
not available in the TAIHOD. Although BMI is a potential covariate of interest, the height/weight 
standards soldiers are required to maintain inherently controls for BMI as a confounder among 
this population. It is possible that women who are assigned to units that participate in above-
average strenuous physical activity or high-intensity field training may be more likely to use 
contraceptives for menstrual regulation and may be at increased risk ACL injury given daily 
physical challenges. The expected result of this confounding would be to underestimate the 
protective relationship. 
Prior literature has considered the role of menstrual phase as a risk factor for ACL injury 
in context of contraceptive use mitigating risk through a casual pathway alerting menstrual phase 
hormonal levels. To date, five studies have considered the timing of injury during the menstrual 
cycle and these studies suggest an increased risk around ovulation though due to inconsistent 
classification of menstrual phase, direct comparisons are difficult. No studies to date have 
identified the luteal phase, where progesterone is high, as increasing risk for ACL injury. It is 
unlikely that menstrual phase is a predictor of contraceptive use and should not be considered a 
confounder. Menstrual phase is not captured in the TAIHOD and the absence of menstrual phase 
as a possible risk factor should not be considered a major limitation.  However, this information is 
critical to consider in context of the other findings. Our results suggest that progestin only 
methods as a class provide the greatest reduction in ACL injury. These findings warrant 
additional consideration of the role of progestin during the menstrual cycle, pregnancy (also a 
period of elevated progestin exposure) and exogenous contraceptive exposure. 
Strengths 
Our study adds to the literature in a number of ways. Prior literature had predominantly 
been limited to ever never use of oral contraception. We considered all hormonal types, the length 
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of use, time since last use and a combination of these factors. In addition, our study included a 
diverse population including women of all different ages and occupations whereas studies before 
2014 had been limited to young athletes.  
Generalizability 
By its nature, this study focuses on a highly selected study sample – female members of 
the active duty Army. To the extent that the biological mechanism by which hormonal 
contraceptives impact risk of ACL injury does not vary by occupation or race or ethnic factors 
associated with armed service membership, the results of this study may be generalizable to all 
women. 
Recommendations for Future Research 
Future research should aim to include a number of covariates not considered in this 
analysis including BMI at time of injury, activity level, and participation in athletics. These 
factors may identify higher risk women both in occupational and recreational setting which we 
were unable to access. Women with knee injury are more likely to have subsequent injury though 
our study did not capture lower extremity injury prior to service and concurrent knee trauma 
(including triad injury) could be a proxy for severity of injury. Timing of pregnancy in relation to 
contraceptive use and ACL injury warrants additional investigation given the protection seen in 
progestin users. Ideally, future work will include detailed contraceptive use at time of ACL injury 
including validation of contraceptive use in pharmacy records by self-report to avoid 
misclassification among women who self-discontinue contraceptive use.  
Conclusion 
To date, few studies have evaluated the association between hormonal contraceptive use 
and risk of ACL injury. Given the serious repercussions an ACL injury may have on a service 
member’s health, fitness, mission readiness and career, it is important to examine preventive 
measures. Due to the large number of contraceptive users, variety of contraceptive options, 
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increased participation of women in the military and the disproportionally high rate at which they 
are discharged to musculoskeletal injury, it is important that the association between hormonal 
contraceptives and ACL injury be fully understood. Reduction of occurrence, frequency or 
severity of ACL injury could also decrease subsequent early onset of osteoarthritis. Results of this 
study suggest contraceptive use may reduce ACL injury by 15%. Hormonal contraception is a 
potentially modifiable risk factor for ACL injury and inform warrant further investigation to 
integrate clinical recommendations and injury prevention strategies.  
Human Subjects Protection 
The TAIHOD database was created in 1994 in order to understand risk factors for injury 
within the active duty Army population. . All active duty army soldiers are included in the 
database without database specific written consent. Study personnel are trained in privacy 
protocols and electronic study database will be stored with a nonmilitary study identification 
number on a secure server that is password protected. There are no known potential risks to 
participants, expect for accidental breach of confidentiality which is unlikely to occur. 
Additionally there is no known benefit to participating in the study except for advancing science 
in research involving servicewomen. This study was approved by the Institutional Review Boards 
of the Unites States Army Research Institute of Environmental Medicine and the University of 
Massachusetts Amherst. 
Permission to Access Data 
Permission to access data was granted by the United States Army Research Institute for 
Environmental Medicine Military Performance Division Chief Edward J. Zambraski, Ph.D. and 
TAIHOD director MAJ Owen Hill Ph.D. MPAS, following IRB approval by USARIEM and the 
University of Massachusetts Amherst. 
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CHAPTER 3 
 
HORMONAL CONTRACEPTIVE USE AND OSTEOARTHRITIS 
 
Introduction 
Osteoarthritis (OA) is a degenerative disease that occurs due to daily mechanical loading, 
overuse and aging (Nevitt & Felson, 1996). OA is a common chronic condition that is 
irreversible. Damage from OA can affect all joints or be site specific. OA is characterized by 
cartilage degradation, inflammation of synovial lining, bone spur formation and decreased muscle 
strength that ultimately can lead to joint failure (Roman-Blas, Castañeda, Largo, & Herrero-
Beaumont, 2009).  OA is diagnosed based on reported pain and diagnostic imagining identifying 
osteophytes (bone spurs), narrowing joint space (loss of cartilage), and changes to bone below the 
cartilage (Scher, Belmont, Mountcastle, & Owens, 2009). The onset of OA is difficult to 
determine as symptoms do not always correlate with radiographic severity. Severe OA based on 
imaging may be asymptomatic, or could be mild to severe friction, aching and pain particularly 
after long bouts of exercise or immobility (Scher et al., 2009).  Incident OA may be untreated for 
years, therefore, first diagnosis is more likely a capture of prevalent cases that became severe 
enough to seek medical attention. OA is treated in an outpatient setting starting with over the 
counter Tylenol or nonsteroidal anti-inflammatories (NSAIDs). OA can be defined as primary or 
secondary. Primary OA is not caused by a preexisting condition, abnormality or disease whereas 
secondary OA follows a pre-existing condition (e.g. hip dysplasia, ACL injury) (Scher et al., 
2009; Lohmander, Englund, Dahl & Roos, 2007). 
Contributing Factors for Osteoarthritis 
Osteoarthritis is a chronic condition that impacts cartilage, meniscus, ligaments and 
muscles around the joint (Heidari, 2010). There are many ways in which OA can manifest and 
many risk factors that contribute to the pathophysiology behind OA onset. Among the many risk 
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factors for OA, being overweight or obese, history of prior joint injuries and having occupations 
requiring knee bending and squatting repeatedly are primary contributors to the development and 
progression of OA (National Center for Chronic Disease Prevention and Health Promotion, 
2014). In addition, older age, female gender, high bone density, muscle weakness, joint laxity, 
vitamin D deficiency and previous pregnancy all contribute to risk, with BMI as the most easily 
modifiable factor (Heidari, 2010). Genetic susceptibility also likely contributes to incidence of 
OA (Heidari, 2010). 
Impact of Osteoarthritis on Public Health and the Military 
OA significantly impacts occupational productivity and accounts for more than half of 
arthritis related hospitalizations, with annual costs for an individual estimated to be between 
$2,650 and $5,700 (Scher et al., 2009). It has been suggested that service members are at 
increased risk for OA given the high physical activity levels related to regular training, fitness and 
weight standards and occupational demands. At entry to the service, new recruits are evaluated 
for preexisting conditions and may be ineligible for service if recurrent, recent or unresolved 
injuries are noted (Scher et al., 2009). As a consequence of the high level of physical training, it is 
well documented that many of these service members will go on to experience a musculoskeletal 
injury during their career.   
OA is typically thought of as a condition that affects sedentary, overweight, and/or 
elderly individuals; however, incidence rates of hip OA were noted at 35 cases per 100,000 
person years (54 cases among women and 32 among men) among service members (Scher et al., 
2009). It has been suggested that occupations requiring repetitive movements (e.g. running or 
loaded physical activity) may increase risk of OA though evidence is limited (Scher et al., 2009). 
Literature has established higher rates of OA among farmers and heavy manual laborers; similar 
trends may be expected among service members given occupational resemblance. More recently, 
literature suggests femoroacetabular impingement (FAI), boney abnormalities that cause friction 
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with motion which may contribute to OA. In a recent study by Scher and colleagues (2009), 
Army servicemen and women had the greatest odds of hip OA over other military branch with 
black service members, women and individuals over 40 years of age at the highest risk (Scher et 
al., 2009). After adjusting for age, rank, race and sex, rates of OA were higher in the Army (RR 
1.9, 95% CI 1.75-2.07), Marines (RR 1.85, 95%CI 1.64-2.09) and Navy (RR 1.63, 95% CI 1.49-
1.78) as compared to the Air Force (Scher et al., 2009). High rates were observed among junior 
enlisted soldiers, which represents a younger population that is more likely to face physical 
demands of combat positions, likely secondary to prior acute musculoskeletal injuries (Scher et 
al., 2009).  OA is particularly important to consider among this population not only due to high 
health care costs, implications for medical readiness and lost duty days, but also due to the long 
term impact on quality of life and future medical costs.  
Gender and Age Differences in Osteoarthritis 
Although it is well known that rates of OA increase with age as a result of compounding 
exposures, literature to date has consistently suggested that women experience a spike in rates of 
OA following menopause greater than expected compared to their age matched male 
counterparts. Women between the ages of 45-64 are 3 times more likely than similar aged men to 
have OA confirmed by diagnostic imaging (Martín-Millán & Castañeda, 2013). Rates of OA in 
the general population spike among women following menopause. Compared to younger women, 
post-menopausal women have more severe self-report symptoms and experience rapid 
progression of the condition (Nevitt & Felson, 1996). Prevalence of symptomatic osteoarthritis 
among adults over 20 in the EPISER study was 10.2%, 14% among women compared to 5.8% 
among men (Martín-Millán & Castañeda, 2013). This was one of the few studies to consider rates 
of OA among younger adults which is more representative of the military population. In the first 
study of  incident OA among service members,  Scher and colleagues (2009) found that women 
had significantly increased rates of incident hip OA compared to men (adjusted incidence rate 
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ratio 1.87, 95% CI 1.73-2.01)  (Scher et al., 2009). Contradicting the literature to date, when 
stratifying by age and gender, servicewomen less than age 20 had the greatest adjusted incidence 
rate ratio compared to servicemen (adjusting for age, service, rank and race) of 5.61 (95% CI 
3.73-8.45) (Scher et al., 2009), with decreasing relative rates when comparing women to men as 
age increased. Given that differential rates of musculoskeletal injury and disability discharge due 
to musculoskeletal injury are observed between service men and women, it is important to 
consider implications of OA as a chronic disease which may have substantial impacts on medical 
cost, occupational productivity and quality of life.  
Prior Knee Injury and Osteoarthritis 
Many studies note prior local injury as of the strongest predictors for future OA. In one 
study 42% of women with history of ACL tear had symptomatic radiographic confirmed knee 
osteoarthritis within 12 years following an ACL injury, irrespective of surgical correction 
(Lohmander, Östenberg, Englund, & Roos, 2004). Women are at greater risk of ACL injury 
compared to men and previous ranges suggest 10-90% of women will have radiographic evidence 
of OA, with three times increased risk of OA in a knee with prior ACL tear as compared to the 
non-injured knee (Barenius, Ponzer, Shalabi,  Bujak, Norlén & Eriksson, 2014). In a recent 
systematic review including 31 studies, OA occurred in 13% of individuals following an isolated 
ACL tear, whereas those who experienced an ACL tear with associated injuries along with a 
meniscus tear had roughly two-fold higher OA prevalence of 21-48% (Øiestad, Engebretsen, 
Storheim & Risberg, 2009).  
Research in this area thus far has focused on predictors of OA among middle aged 
women in civilian populations, failing to adequately account for potential hormonal exposures 
outside of hormone replacement therapy (e.g. hormonal contraception). The unique occupational 
and physical demands that young service members face make this population particularly relevant 
to consider. To our knowledge, no research to date has examined predictors of knee OA among 
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service members. The purpose of this study was to identify predictors of knee and hip OA, with a 
focus on the impact of hormonal contraception among active duty army servicewomen. Results of 
this study add to the limited literature to date and aid in contraceptive decision making among 
women at high risk for osteoarthritis.  
Physiology of Hormonal Contraceptives and Osteoarthritis 
It is well understood that the rates of osteoarthritis increase disproportionately among 
women during and following menopause. Consistent documentation of increased rates of 
generalized OA among post-menopausal women has implicated sex hormones as a significant 
contributor in the development and severity of OA (Nevitt & Felson, 1996). This has led 
researchers to evaluate fluctuations in endogenous hormonal profiles during menopause as well as 
use of exogenous hormone replacement therapy and OA risk. However, literature to date provides 
conflicting evidence for the existence of a relationship studies considering the role of other sex 
hormones from contraceptive use have been limited.  
Role of Estrogen on Joint Integrity 
Estrogens act directly and indirectly on tissue impact normal cell growth and 
development which impact degenerative diseases (Martín-Millán & Castañeda, 2013). The role of 
estrogen on inflammation and immune disease is unclear, however the increased prevalence of 
autoimmune diseases among women and increased rates of OA are evidence that some 
relationship may exist (Martín-Millán & Castañeda, 2013). Two types of estrogen receptors (α 
and β) are found in the joint, on bone, growth plates, chondrocytes and synoviocytes (Martín-
Millán & Castañeda, 2013). Data suggest that estrogen decreases cartilage damage, regulates 
bone growth, and retains bone mineralization preventing bone attrition, enhances muscle 
performance and structure in women. In mice, estrogen has been shown to reverse damage 
associated with autoimmune arthritis in the synovium. Conflicting findings have been reported on 
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effect of estrogen on ligaments with a trend toward high menstrual cyclic levels increasing risk 
for ACL rupture (Martín-Millán & Castañeda, 2013). 
Role of Endogenous Hormones: Menopause 
Given that menopause has been the most widely studied hormonal risk factor for OA it is 
relevant to understand the physiological mechanism proposed to drive this association. It is 
suggested that excess or unopposed oestrogens may influence risk of OA through receptors on 
articular chondrocytes or indirect pathways including cytokine levels and cartilage metabolism 
(Nevitt & Felson, 1996). However, no association between testosterone or oestradiol levels and 
knee OA have been found and case control studies show no relationship between time since 
menarche to menopause and parity with OA (Wluka, Cicuttini, & Spector, 2000). In the peri-
menopausal period, progesterone levels rapidly decline and estrogen remains stable. After some 
time, significant variations occur with serum estrogen until eventually estrogen stabilizes at lower 
levels than before the onset of menopause. It has also been noted that this decrease of circulating 
hormones can alter joint structure. Animal studies suggest that extremes of hormonal exposure 
(both high and low) could adversely impact the integrity of the joint structure and function 
leading to increased risk for OA (Roman-Blas et al., 2009).  
Many studies had been published to evaluate the use of HRT on hip and knee OA with 
conflicting results. A meta- analysis conducted in 1996 to synthesize available data from 
observational studies found a summary OR estimate of 0.76 (95% CI: 0.63-0.91), suggesting 
decreased risk of OA among hormone replacement therapy users compared to non-users (Nevitt 
& Felson, 1996). Menopause has been the primary time-frame of interest when considering OA.  
However, hormonal contraceptive use also alters endogenous hormone levels, and for potentially 
longer periods of time than menopause.  
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Hormonal Contraception and Osteoarthritis 
Research is limited on the association between hormonal contraceptive use and OA, but 
previously discussed research of endogenous hormones and HRT and OA risk provide a potential 
physiological mechanism for the association. Both the acute effects of contraception on joint 
integrity during a menstrual cycle as well as long term effects on bone density and joint 
degradation may reduce or increase subsequent risk for OA development. Hormonal 
contraception is known to attenuate the hormonal spikes that women experience during a 
menstrual cycle. This acute impact on endogenous hormone levels has been suggested to stabilize 
joint laxity and strength within a cycle which may not only reduce risk for a traumatic 
musculoskeletal injury but also reduce micro-damage to joint tissue over time, reducing the long 
term risk of OA. However, given the availability of contraceptive options, it is important to 
differentiate between specific types (e.g. combined hormonal contraception and progestin only). 
Combined hormonal contraceptives containing estrogen and progesterone have relatively stable 
pre-set doses of both hormones that are administered on a daily (pill) weekly (patch) or monthly 
(ring) basis. The estrogen provided directly from these contraceptives may directly impact joint 
structural integrity and therefore impact mechanical loading and subsequent risk for OA. It is 
possible that short term use of combined hormonal contraception decreases risk for OA. 
However, long term use of estrogen containing contraception may increase risk for OA, 
particularly after prolonged use. Combined hormonal contraception is noted to stimulate 
osteoblasts which increases bone mineralization (preventing attrition) increasing bone density. 
Progestin only methods, including the pill, injection, implant and Mirena (IUD) should be 
considered separately from combined methods particularly when considering an association to 
OA. Not only do these methods lack estrogen,  which changes the impact on endogenous monthly 
cyclic fluctuations and joint tissue, but all these methods (except the pill) are administered over 
prolonged periods of time where the level received may greatly vary from start to end of effective 
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use. In addition, prolonged use of depo Provera (the injection) is linked to loss in bone mineral 
density. Lower bone mineral density, increasing risk for osteoporosis, is inversely related to 
osteoarthritis given the reduced bone stress, stiffness and mechanical loading (Wluka et al., 
2000).   
Given the widespread use of hormonal contraceptives among servicewomen and the 
potential implications on chronic joint degradation it is important to better understand this 
relationship. The Total Army Injury Health Outcomes Database (TAIHOD) provides a large 
sample of young, highly active women to examine this association with up to 10 years of 
prospective data capture on pharmacy and clinical records.  
Epidemiology of Hormonal Contraceptives and Osteoarthritis 
Between 1993 and 2017, eleven epidemiological studies assessed the association between 
hormonal contraceptive use and OA (Vingård, Alfredsson, & Malchau, 1997; Dennison, Arden, 
Kellingray, Croft, Coggon & Cooper, 1998; Karlson, Mandl, Aweh, Sangha, Liang & Grodstein, 
2003; Cooley, Stankovich & Jones, 2003; Liu, Balkwill, Cooper, Roddam, Brown, Beral, & 
Million Women Study Collaborators, 2009; Hellevik, Nordsletten, Johnsen, Fenstad, Furnes, 
Storheim, ... & Langhammer, 2017; Dawson, Juszczak, Thorogood, Marks, Dodd & Fitzpatrick, 
2003; Sandmark, Hogstedt, Lewold & Vingard, 1999; Samanta, Jones, Regan, Wilson & Doherty, 
1993; Wei, Venn, Ding, Martel-Pelletier, Pelletier, Abram, ... & Jones, 2011; Jung, Shin, Lee, 
Kim, Park, Choi, ... & Ha, 2015). Many of these studies considered other life course hormonal 
exposures including age at menstruation, parity, age at menopause, hormone replacement therapy 
use in addition to contraceptive use. Five of these studies were case-control in design (Vingård et 
al., 1997; Dennison et al., 1998; Dawson et al., 2003; Sandmark et al., 1999; Samanta, et al., 
1993), three were cohorts (Karlson et al., 2003; Liu et al., 2009; Hellevik et al., 2017) and three 
were cross-sectional studies (Cooley et al., 2003; Wei et al., 2011; Jung et al.,, 2015). Most 
studies selected participants based on wait list status for joint replacement or recent surgery, 
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resulting in subjects being middle aged to elderly. Of the eleven studies, the most recent found a 
statistically significant association where oral contraceptive use increased the risk for total knee 
replacement (TKR) HR 1.37 (95% CI 1.03-1.84) (Hellevik et al., 2017). Of the remaining ten 
studies, four observed point estimates indicating reduced risk of OA with OC use (Cooley et al., 
2003; Dawson et al., 2003; Sandmark et al., 1999; Samantha et al., 1993), three observed point 
estimates suggesting increased risk for OA with OC use (Vingard et al., 1997; Dennison et al., 
1998), and four observed point estimates very close to null (Karlson et al., 2003; Liu et al., 2009; 
Wei et al., 2011; Jung et al., 2015). In these eleven studies, OA was evaluated in the knee only 
(Dawson et al., 2003; Sandmark et al., 1999; Samanta et al., 1993; Jung et al., 2015; Wei et al., 
2011), knee and hip (Liu et al., 2009; Hellevik, et al., 2017), hip only (Vingård et al., 1997; 
Dennison et al., 1998; Karlson et al., 2003), and hand (Cooley et al., 2003). These eleven studies 
are described below and grouped by the joint in which OA was assessed. 
Oral Contraceptive Use and Hip and Hand Osteoarthritis 
Three studies to date have evaluated the relationship between oral contraceptives use and 
OA of the hip. Two of the three studies suggest that oral contraceptives increase risk of hip OA 
(Dennison et al., 1998; Karlson et al., 2003), with a borderline significant increase in risk 
observed in one study (Vingård et al., 1997). A case-control study (n=503) conducted by Vingård 
and colleagues (1997) assessed the relationship between hip arthrosis, hormone use, BMI and 
smoking among 230 cases and 273 controls and found that use of contraceptives for 1 year or 
more before the age of 50 conveyed an OR of 1.6 (95% CI 1.0-2.3) (Vingård et al., 1997). The 
authors also found an association between high BMI in early life and increased risk of subsequent 
hip arthrosis. 
In 1998, Dennison and colleagues conducted a population based case-control study 
(n=816) to assess the relationship between OC use and other reproductive variables and 
symptomatic hip OA (Dennison et al., 1998). In an analysis comparing the 10% of women who 
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had used oral contraceptive pills with non-users that adjusted for BMI, Herberden’s nodes, prior 
hip injury, leisure activity and all other reproductive variables, a non-statistically significant 
increase in risk of hip OA was observed for contraceptive users (OR 1.6, 95% CI 0.8-2.9) 
(Dennison et al., 1998). This study collected data on length of oral contraceptive use but did not 
report the results. Karlson et al. conducted the most recent study on oral contraceptive use and hip 
OA among 121,701women in the Nurses’ Health Study (Karlson et al., 2003). Women in the 
highest BMI quintile at age 18 had a five-fold increase in risk of total hip replacement due to OA 
when compared to the lowest BMI quintile (<22 kg/m2 versus ≥35 kg/m2). Smoking, physical 
activity and hormone use were not associated with risk of a hip replacement.  
Only one study to date has considered the relationship between hormonal factors and 
hand osteoarthritis. In 2003, Cooley and colleagues published a cross-sectional study of 348 
Tasmanian women (Cooley et al., 2003). They recruited incident hand OA cases (index cases) as 
well as affected (non-index cases) and unaffected family members. They considered age at 
menarche, parity, breastfeeding, oral contraceptive use, age at menopause, years of menstruation, 
hysterectomy and HRT use as hormonal exposures of interest. Prevalence and severity of OA 
progression increased with parity, age at menopause, years between onset of menarche and 
menopause, as well as HRT use. Breastfeeding was found to be protective. Non-index cases 
(n=272), including both affected and unaffected family members were significantly more likely 
(p<0.001) to be ever oral contraceptive users (83%) as compared the proportion of ever users 
(24%) among cases (n=76). However, there were no statistically significant differences between 
oral contraceptive use (yes/no) for distal inter-phalangeal joint space narrowing (OR 0.8, 95% 
CI0.27-2.34), nor was there an association with duration of OC use (Cooley et al., 2003). 
Although mechanical loading experienced by the hand is not comparable to lower extremities it 
may still be of physiological relevance to consider other anatomical locations given the 
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potentially comparable mechanism by which circulating serum hormones impact chondrocyte 
metabolism.  
The results of the three studies considering hip OA may be important to consider when 
evaluating contraceptive use and knee OA given the proximity of the joints and compensatory 
behaviors that may occur during weight bearing activity that impact proximal and distal 
segments. Because of differences in the structure and function of the hand and hip versus knee 
joint, the predictive factors for hip OA may not apply similarly for OA of the knee, but may 
provide insight to the physiological mechanism.   
Oral Contraceptive Use and Knee Osteoarthritis 
Seven studies to date have considered the association between oral contraceptives use and 
knee osteoarthritis, two which also consider hip OA. Three case control studies yielded non-
significant results with point estimates suggesting protective effects of oral contraceptives use 
(Samanta et al., 1993; Sandmark et al., 1999; Dawson et al., 2003). Two cross sectional studies 
found null results (Wei et al., 2011; Jung et al., 2015). The one prospective cohort found null 
results (Liu et al., 2009) and the most recent cohort found a statically significant increased risk of 
OA with hormonal contraceptive use (Hellevik et al., 2017).  
A case-control study (n=690) conducted in 1993 utilized mailed surveys to assess the 
relationship between sex hormones, smoking and OA among women (Samanta et al., 1993). The 
authors identified women with nodal generalized OA and (NGOA) as well as non-nodal 
pauciarticular large joint OA (LJOA) from an OA research clinic in Nottingham. The authors 
randomly selected three age-matched controls from medical records and mailed questionnaires to 
all 1096 cases and controls.  A final sample size of 690 included: 95 NGOA cases (74% response 
rate) and 226 NGOA controls (58%), 113 LJOA cases (78%) and 256 LJOA controls (59%). 
NGOA most often develops around menopause and involves many small and large joints, 
whereas LJOA has no apparent correlation with menopause. The authors found that fewer LJOA 
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patients had ever smoked and prior successful pregnancy was protective against NGOA. Oral 
contraceptive use was not significantly associated with LJOA (OR 0.81, 95% CI 0.22-2.0) or 
NGOA (OR 2.0, 95% CI 0.63-6.37) (Samanta et al., 1993). Of note, this study included 
disproportionately low numbers of OC users, with less than 10% reporting any lifetime use, 
which would decrease statistical power, already limited by the modest overall sample size. 
Second, differing response rates by cases and controls (74 to 78% versus 58 and 59% 
respectively) raises the possibility of factors related to participation as a source of bias. Sandmark 
and colleagues considered knee OA in men and women (n=584) with a primary focus on weight, 
smoking and hormone therapy use (Sandmark et al., 1999). This case-control study included 300 
female cases identified through a Swedish knee arthroplasty registry who were between 55 and 70 
at the time of surgery, and 284 controls randomly selected from the population. Women in the 
highest quartile of BMI (≥24 kg/m2) at the age of 40 had almost ten times the risk for severe knee 
OA later in life compared to the lowest quartile (≤21 kg/m2) and, consistent with Samanta, 
smokers had lower risk than non-smokers. Women who used oral contraceptives pills for at least 
one year had similar risk of severe OA requiring knee surgery compared to non-users (RR 0.9, 
95% CI 0.6-1.4) (Sandmark et al., 1999). Similar to Samanta, a small portion of the population 
was exposed to contraceptives and only 15% of cases and 17% of controls reported used OC. 
In 2003, Dawson and colleagues examined risk factors for symptomatic knee 
osteoarthritis using a matched case-control design (n=101) (Dawson et al., 2003). The primary 
objective of their study was to consider the association between high heeled shoes and 
symptomatic knee OA. Cases were identified from a waiting list for total knee replacement and 
were restricted to those with moderate knee pain most days of the month. Controls were selected 
from general practice and matched by age to cases. The final sample size included 29 cases and 
82 controls. Oral contraceptive use (ever/never) was not significantly associated with 
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symptomatic knee osteoarthritis (OR 0.87, 95% CI 0.35-2.15) (Dawson et al., 2003). This study 
was limited in power given the small sample size.  
Liu and colleagues (2009), considered the relationship between contraceptive use and OA 
in the largest prospective cohort study to date (n=1.3 million). The authors examined the effect of 
reproductive history and use of hormones on risk of hip and knee joint replacement due to 
progressive OA (Liu et al., 2009). The authors included women in their 50s (average age = 56) 
and followed them for about 6 years. The study found an association with parity, with risk of joint 
replacement increasing by 2% (1 to 4%) per birth for hip OA and 8% (6 to 10%) for knee. Early 
menarche (<12) was also observed to be related to increased risk of hip and knee replacement. 
Menopausal status was not associated though current used of HRT increased risk of hip and knee 
replacement by 38% and 58% respectively. Women with hip and knee replacements were less 
likely to have used oral contraceptives; however, these associations with prior oral contraceptive 
use were not significant for either hip replacement (RR 1.02, 95% CI 0.98-1.06) or knee 
replacement (RR 1.0, 95% CI 0.96-1.04).  This study also considered duration of contraceptive 
use in categories of <5 years, 5-9 years and 10+ years. There were significant linear trends for 
increasing risk of hip and knee replacements with increasing duration of use (p=0.03 and p=0.05 
respectively), though none of the individual categories reached statistical significance. Though 
this study included a very large sample size, subjects were racially homogenous and limited 
consideration to OA that required hip or knee replacement. 
Jung and colleagues (2015) used a cross-sectional approach (n=5,449) to consider the 
impact of pregnancy, parity (including abortions) and contraceptive use among Korean women at 
least 50 years old. The authors collected information on contraceptive use from the 5th Korean 
National Health and Nutrition Examination Survey and completed x-ray imaging of the knee to 
identify OA. They found no significant association between oral contraceptive use and OA (OR 
1.00, 95% CI 0.83-1.2) after adjusting for age, income, education, BMI, smoking and mental 
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health.  Although this study was large, the limitation of temporal bias associated with cross 
sectional designs cannot be overlooked (Jung et al., 2015). 
Wei and colleagues (2011) conducted a population based cross-sectional study (n=489) 
with women 50-80 years of age. The authors considered hormonal exposures including parity, 
contraceptive use and HRT with knee OA. They used x-ray and MRI to assess volume of 
cartilage, joint space narrowing, and osteophytes.  Although x-ray is the gold standard, MRI is 
able to quantify volume. Oral contraceptive use was not associated with cartilage volume, 
cartilage defect or radiographic change. Ever use of OC was not significantly associated with 
knee OA after adjustment for age, BMI, smoking, parity, pain score and use of HRT (OR 0.88, 
95% CI 0.38-2.06). Parity was associated with a decreased volume and BMI was associated with 
increased OA risk. This study utilized detailed objective assessment for OA however, this does 
not measure functional impairment (Wei et al., 2011). 
Most recently, Hellevick and colleagues (2017) conducted a cohort study (n=30,289) 
including women over the age of 30. The authors examined the relationship between self-reported 
contraceptive use and eventual total knee replacement (n=430) or total hip replacement (n=675). 
Ever users of hormonal contraceptive had an increased risk for total knee replacement (HR 1.37, 
95% CI 1.03-1.84) and a non-statistically significant increased risk for OA leading to total hip 
replacement (HR 1.11 95% CI 0.87-1.42) after adjusting for age, BMI, smoking and physical 
activity compared to never users. Although this study considered both knee and hip OA, it failed 
to capture non-surgical cases of OA and the average age of cases was 64 with remote timing of 
contraceptive use limited to high dose pills. 
In summary, evidence for the association between oral contraceptives use and knee and 
hip OA is limited; eleven epidemiological studies have considered this association, but small 
sample size and low prevalence of oral contraceptive use or cross-sectional study designs limited 
inferences. In addition, most of these studies were conducted with self -report dichotomized 
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exposure of contraceptive use yes/no, rather than more complete information including 
contraceptive type. In addition, despite some studies that have considered duration of OC use 
(Cooley et al., 2003; Liu et al., 2009; Wei et al., 2011), its relation with OA risk remains unclear. 
No study to date has considered contraceptive methods other than the oral contraceptives pill. The 
age range of these populations has been limited to women in their 50s to 70s. Moreover, these 
women represent prevalent, rather than incident, cases of OA. Additionally, changes in 
pharmaceutical composition of contraceptive and contraceptive type availability may be 
important to consider given the exposure window for contraceptives use represented by study 
populations to date. 
Aim and Hypotheses 
Specific Aim: To evaluate the association between hormonal contraceptive use and risk 
of knee and hip osteoarthritis among active duty servicewomen. Hypothesis 1: Compared to non-
contraceptive users, rates of OA will be lower among hormonal contraceptive users. Hypothesis 
2: Compared to combined hormonal contraceptive users, rates of OA will be lower among 
progestin only method users. Hypothesis 3: Rates of OA will be lower among those with longer 
duration of contraceptive use compared to those with shorter durations of use.  
Methods 
Study Design and Population 
Using a retrospective cohort design, we assessed the relationship between hormonal 
contraceptive use and risk of osteoarthritis among active duty Army female soldiers age 17 to 45 
who served on active duty for at least two months between January 1st, 2002 and December 31st, 
2011 captured in the TAIHOD. The TAIHOD was created in 1994 to study injuries among female 
soldiers, though the database captures servicemen and women. The database prospectively links 
administrative, clinical, pharmaceutical, occupational and health behavior data for all soldiers 
who have been on active duty. The TAIHOD currently contains data on over 5 million soldiers 
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with active service and outpatient clinical records as far back as 1997. The start date of January 
1st, 2002 was selected as it marks the onset of electronic pharmacy record capture from the 
Pharmacy Data Transaction Service (PDTS), which is integrated into the TAIHOD to determine 
hormonal contraceptive use. This timeframe captures Operation Enduring Freedom and Operation 
Iraqi Freedom (OEF/OIF), which allows for evaluation of changes in contraceptive preference 
and use in austere environments as well as changes in number and frequency of deployments. It 
also provides a timeframe with potential periods of increased injury rates given the increased 
frequency of training and deployment.  
Among active duty Army soldiers between 2002 and 2011, there were a total of 207,777 
women. In any given year during this 10 year period, about 82,000 women were on active duty; 
servicewomen comprised between 13.6-15.8% of the active duty Army over the ten-year study 
period. Two thirds of the women on active duty between 2002 and 2011 were new accessions, 
entering the cohort in 2002 or later. The average age at entry into the cohort was 24. Most women 
had high school education or equivalent at entry. Less than one quarter of women had a rank of 
senior enlisted or officer at entry. At entry, 30% were overweight or obese. More than half were 
ever deployed at least once during the cohort and one quarter had a delivery during the cohort. 
Half had a documented knee injury during the cohort, 30% had a back injury and 15% an ankle. 
Most women ever used NSAIDs during the cohort. 
Exclusion 
For the purpose of the current study, women with only one record in the DMDC were 
dropped due to the insufficient observation time to capture and quantify hormonal contraceptive 
use, changes in duty station, and other undetermined cause for military discharge that make these 
women not representative of the active duty women who serve for longer periods of time. In 
order to restrict consideration to pre- and not peri-menopausal women, women were censored 
from the analysis at the age of 46. Thus, women who entered the cohort at age 46 did not 
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contribute any observation time to the study; however, women who turned 46 during the study 
timeframe contributed person time up until censoring at age 46, with subsequent person time 
dropped. Participants who were missing age, education, marital status, race or ethnicity from the 
DMDC were excluded. From this population, we further excluded women who had medical 
record documentation of a hysterectomy, oophorectomy, clinically diagnosed menopause, or used 
hormone replacement therapy as these women likely have different comorbidities that may 
impact their use of hormonal contraceptives. In addition, women who experienced one of these 
events during the study cohort were dropped at the event date and person time following the event 
was censored. Women with greater than 120 pregnancy visits during the study cohort were also 
excluded. These women compromise a group of either implausible medical records or high risk 
pregnancies that are likely not generalizable.  Although rare, women with any lower extremity 
amputation were excluded or dropped as their risk for osteoarthritis is expected to be vastly 
different compared to other servicewomen. Women with known OA prior to 2002, contralateral 
or recurrent injury, were dropped to identify incident ever OA. The number of women and person 
years excluded and dropped are shown in Table 12. 
Exposure Assessment: Hormonal Contraception 
Hormonal contraceptive use was assessed through pharmacy data recorded in the PDTS 
within the Medical Data Repository. The PDTS is a complete database capturing all prescription 
pick-ups at Military Treatment Facilities, TRICARE pharmacy networks, and mail orders 
(Department of Defense, 2009; The Department of Defense Pharmacoeconomic Center, 2011). 
Pharmacy records contain information on: therapeutic class, product name, type of hormonal 
contraceptive, dosage, days’ supply, quantity and date pick up. TRICARE covers hormonal 
contraceptives at no cost to soldiers (Enewold et al., 2010). Therapeutic class codes ‘681200, 
contraceptives’ and ‘683200, progestins’ were used to identify hormonal contraception. 
Prescriptions recorded with a dispense quantity equal to zero were considered as requested but 
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not picked up. Prescriptions for HRT or treatment for amenorrhea and anovulation were not 
included in the analysis as hormonal exposure.   
The PDTS dataset contains information on the date, quantity and contraceptive type 
dispensed. Estrogen containing product type other than: pill, patch, injectable, implant, vaginal 
ring (e.g. estrogen gel) were categorized as non-contraceptive users. Exposure was further 
categorized by type of contraceptive to evaluate differences in use of combined hormonal 
contraceptive versus progestin only. Combined hormonal contraceptives included monophasic, 
biphasic and triphasic oral contraceptives, Ortho-Evra (birth control patch), and Nuvaring. 
Progestin only contraceptives include progestin only pill, Depo-Provera (injection), Mirena 
(intrauterine device) and implants (including: Noroplant, Implanon and Nexplaon). Timing and 
duration of use was determined from start and stop dates were calculated as follows: start date 
equals date of pick up plus one day and the end date is equal to the start date plus the quantity 
provided.  
For consistency with prior literature, we initially dichotomized hormonal contraceptive 
use as ever versus never user. Taking advantage of the extensive information included in the 
TAIHOD, we additionally considered use as ‘never’, ‘past’ and ‘current’, as well as contraceptive 
type (pills type, patch, ring, injection, IUD and implant). These methods were collapsed into 
combined hormonal contraceptive and progestin only. We also looked at duration of any 
contraceptive use as defined by short (<90 days), medium (90-365 days) and long (365+ days). 
Prior studies have identified 90 days as an appropriate cut point for short use as women are often 
encouraged to trial a new method for at least 3 months and 97% of those using fgor 3 months will 
continue using in month 4 (Rosenberg & Waugh, 1998). To examine the impact of never versus 
current use, the variable ‘never past current’ was combined with both type and duration. Prior 
studies have not considered dose of contraceptives which is equivalent to the duration of use by 
type of use. To examine dose we created a 10 level mutually exclusive variable that incorporates 
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both type of method and duration of use. Our final categorization of contraceptive use evaluated 
time since stopping use of any contraceptive method (Table 15).  
Validity of Exposure 
Hormonal contraceptive pharmacy records have not been validated in the TAIHOD. 
However, previous research have suggested that pharmacy records are a valid source of 
information regarding use, duration and timing of contraceptives when compared to self-report 
(which is the most frequently utilized method of exposure assessment).  Discordance between 
pharmacy records and self-report may result from inaccurate self-reporting, or when prescriptions 
are filled but not used. Pharmacy records have also been found to be a more accurate source of 
information than self-report for type of oral contraceptives (high dose, low dose and progestin 
only pill), with correlation coefficients between self-report and pharmacy records ranging from 
0.84-0.93 (Norell, Boethius & Persson, 1998). Use of pharmacy records for assessment of 
duration of use requires assuming that any prescription dispensed was used for the entire days’ 
supply as directed by the pharmacy. 
Outcome Assessment: Osteoarthritis 
OA was identified by international ICD-9 code 715 in medical records. OA cases were 
further classified with the fourth digit of the ICD-9 codes as 1 (localized, primary, idiopathic), 2 
(localized, secondary), 3 (localized, unspecified), 9 (unspecified whether generalized or 
localized). The fifth digit of the ICD-9 code allowed for identification of the affected area of the 
body pelvic region and thigh cases (5) as well as lower leg cases, including the area below the 
thigh and above the ankle (6).  The first date of service for this ICD-9 code was selected to 
identify the initial time of diagnosis (Table 13). Prior literature suggests identification of OA 
through medical records is superior to self-report. Clinical encounter billing codes for women 
who had been on active duty prior to 2002 were reviewed to exclude prior OA.  
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Covariate Assessment 
Demographic data including age, race, ethnicity, education, marital status, grade and 
length of service were extracted from the monthly DMDC data repository. When a service 
member joins the military without any previous military they are considered to be a new 
accession. For new accessions, length of service represents the time in the study cohort between 
2002 and 2011. For women with active duty time prior to 2002, length of service represents the 
sum of all time on active duty prior to and including the cohort timeframe  Ever attendance to 
basic combat training was identified from training records, however, dates of BCT were 
determined as discussed above. Deployment records and overseas station dates and location were 
merged with DMDC records. A single measurement of body mass index (BMI), as measured at 
accession, was also merged with the demographic data.  Diagnostic and medical procedure billing 
codes from the time a woman entered active duty were available and utilized to identify lower 
extremity injury and delivery (Appendix A). Records for women who served on active duty prior 
to 2002 were included to capture the number of deliveries and lower body injuries prior to the 
cohort. Parity was determined by the number of dependents, marital status, age and delivery 
during the study cohort. Specifically, women with a known delivery during the study are 
automatically parous. Women without any documented deliveries, but were married with 2 or 
more dependents were also considered parous. Women who were, single with no dependents 
were considered nulliparous. Ever use of prescription NSAIDs and count were also determined 
from pharmacy records. 
Univariate Analysis 
We reported the number, percent  and total active duty person years in TAIHOD and the 
number and percent of those who are excluded due to missing records, age over 45, previous 
hysterectomy, oophorectomy, menopause, hormonal therapy, lower extremity amputation and 
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previous osteoarthritis (Table 12). The percent distribution of OA by primary location and type 
were presented (Table 13).  
Bivariate Analysis 
The association between entry covariates and osteoarthritis was assessed through chi-
square tests and results of the cross tabulation were reported (Table 14). Percent and distribution 
of hormonal contraceptive exposure by osteoarthritis are presented across all contraceptive 
categorizations. Unadjusted relative risks and 95% confidence intervals were calculated to 
compare hormonal contraceptive users with non-users as the reference group, with regard to OA 
(Table 15). 
Multivariable Analysis 
The relationship between hormonal contraceptive use and OA was modeled using 
survival analysis to estimate hazard ratios and 95% confidence intervals (Table 15). Nine 
categorizations of contraceptive exposure were considered in this analysis. Potential confounders 
were identified as being significantly related to both contraceptive use and OA. The only 
confounder consistently identified by prior literature is age, which a priori was retained in the 
final model. Likelihood ratio tests comparing models with these covariates to the hormonal 
contraceptive ever/never model were conducted and models that remained significant (p<0.05) 
were retained for continued step-wise model building. The variables for the final model of 
hormonal contraceptive ever/never were then applied to the eight remaining categorizations of 
contraceptive exposure. 
Three models were considered in the final set of analyses including: 1) unadjusted; 2) age 
adjusted; and 3) final adjusted model. A sensitivity analysis considered only new accessions 
during the study cohort to capture the full spectrum of career events servicewomen face to ensure 
inclusion of basic training, advanced individual training and deployment where both 
contraceptive use and risk for ACL injury may differ from permanent duty station (Table 16).  
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Results 
Final Study Sample 
Exclusions are detailed in Table 12. Of the 207,777 participants and 757,610 person years 
of total observation, the most common reason for exclusion was due to missing records 
(n=6,347). Over one third of those excluded (n=3,544) only had one month record in DMDC. An 
additional 2,803 women were missing age, education, marital status, race or ethnicity. An 
additional one percent of women were excluded from the study due to being age 46 or older at 
entry to the cohort or to the Army. Less than one percent of the study population was excluded 
due to a medical reason. A total of 80 women were excluded from the study due to lower 
extremity amputation and an additional 1,010 women were excluded due to known prior OA 
before 2002. Half of the women excluded at entry and the majority of women dropped during the 
study time frame had service prior to 2002 (Table 12). 
Osteoarthritis 
We identified 196,306 eligible women in the TAIHOD between 2002 and 2011 resulting 
in 706,978 person years of observation (Table 12). Of eligible women, 3,943 experienced 
incident OA, representing a rate of 558 per 100,000 per years among the entire cohort and a rate 
of 362 per 100,000 among new accessions (Table 13). Most incident cases of OA were identified 
in the lower leg (80.62%) without specified type (65.37%). Compared to the entire cohort, new 
accessions had a greater proportion of OA cases occurring in the pelvic and thigh region (19.38% 
vs. 26.70% respectively). 
Correlates of Osteoarthritis 
Compared to women without OA, women with OA had 30% higher probability of service 
prior to 2002 (64.95% vs. 34.38%). These women were on average almost six years older, had 
higher education, marital status and rank. Women with OA were more likely to be African 
American (50.87% vs 32.32%), 12% more likely to have prior back or hip injury as well as with a 
 79 
prior knee, or leg injury. Women with incident OA had 17% higher likelihood of being 
overweight or obese at entry to the Army (47.73%) compared to women without OA 
(29.95%).Women with OA were twice as likely to be parous at entry (31.63% vs 15.31%) and 
twice as likely to ever be pregnant while on active duty (31.63% vs. 15.31%) (Table 14). 
Hormonal Contraceptive Use and Osteoarthritis: Ever Use 
Ever users of hormonal contraception had a 7% increased risk of OA compared to never 
users of hormonal contraceptive (HR 1.07, 95% CI 0.99- 1.14) though the results were not 
statistically significant in the unadjusted model (Table 15). After adjusting for age, knee (never, 
past, current injury), back or hip (never, past, current injury), leg or ankle (never, past, current 
injury), NSAID use, new accession, deployment, education, BMI, marital status, race, parity and 
rank, findings were opposite as seen in the unadjusted model, and a protective effect was seen. 
Specifically, ever users of contraception had a 19% decrease in OA (HR 0.81, 95% CI 0.76-0.87) 
which remained stable regardless if use was current or past (Table 15). Among new accessions 
(Table 16) a non-significant 12% decrease in risk was seen among ever users (HR 0.88, 95% CI 
0.78-1.00). The key covariates responsible for the reversal of effect were: new accessions, prior 
knee injury, back or hip injury and NSAID use.  
Hormonal Contraceptive Use and Osteoarthritis: Type of Use 
In the unadjusted model, hazards were highest among women who ever used both 
combined contraception and progestin only (HR 1.11, 95% CI 1.01-1.22) and no specific type of 
contraception demonstrated any statistically significant association with OA. However, in the 
final adjusted model, women who ever used both types of contraception had the lowest risk of 
OA (HR 0.7, 95% CI 0.63-0.77). The patch and IUD were both significantly associated with OA 
(HR 0.73, 95% CI 0.57-0.94) and (HR 0.77, 95% CI 0.49-0.92) respectively in the final adjusted 
model. These trends remained similar in the sensitivity analysis, however, the magnitude of ever 
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using both contraceptives was attenuated (HR 0.79, 95%CI 0.66-0.94) and there was no single 
type of contraception associated with OA. 
Hormonal Contraceptive Use and Osteoarthritis: Duration of Use 
In the unadjusted full model, increasing length of use of any hormonal contraception was 
associated with increasing risk of OA whereby women who used contraception for at least a year 
had 28% increased likelihood of OA (HR 1.28, 95% CI 1.18-1.38) compared to never users. 
Similarly increased risks were observed regardless of past or current use and regardless of type of 
use (combined only, progestin only or both). However, in the final adjusted model, there was an 
increasingly protective effect of contraception as duration of use increased. Women using 
contraception longer than 1 year were observed to have a 21% lower risk of OA (HR 0.79, 95% 
CI 0.73-0.86). The greatest reduction in risk was among women who ever used both methods for 
over 1 year (HR 0.68, 95% CI 0.60-0.77). These trends remained stable in sensitivity analysis 
among new accessions only. 
Discussion 
Summary of Findings 
In this large retrospective cohort study including nearly 200,000 US servicewomen, we 
observed an inverse relationship between OC use and risk of OA. Ever users of hormonal 
contraceptive had 19% decreased likelihood of OA as compared to never users in the final 
adjusted model, which was opposite of the unadjusted model due to key covariates including new 
accession, prior injury and NSAID use. With regards to type of contraceptive use, women who 
used both combined and progestin only during their career had the lowest hazard with a 30% 
decrease compared to never users. As duration of contraceptive use increased hazard of OA 
decreased, where by women with cumulative contraceptive use of at least 1 year were 21% less 
likely to be diagnosed with OA.  
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Consistency with Prior Literature 
The unadjusted HR suggests there is a non-significant increased risk of OA among 
contraceptive users which is generally consistent with prior literature. However, in our final 
model, we find there is a 19% reduction in OA among ever users of contraception. Our 
unadjusted results were similar to the only study to find statically significant association between 
oral contraceptive use and total knee replacement which suggested a 37% increase in risk 
(Hellevik et al., 2017). In addition, Vingard et al. (1997), looked at oral contraceptive use and hip 
replacement has and found a borderline significant 60% increased risk.  
Prior literature suggest that incidence rates of hip OA were noted in up to 88 cases per 
100,000 person years among servicewomen members (Scher et al., 2009), whereas knee OA was 
observed in the general population at a rate of 20 per 100,000 person years (Oliveria, Felson, 
Reed, Cirillo, & Walker, 1995). Although we identified rates of hip OA at 108 per 100,000 
similar to previously reported rates in the military, we found rates of knee OA to be more than 20 
times previously documented in the general population (449 per 100,000).  Similar to prior 
literature, we found that increasing age, pregnancy and BMI were associated with OA (Heidari, 
2010) and a disproportionate rate of black service members diagnosed with OA (Scher et al., 
2009). Our results do not agree with Scher and colleagues (2009) where we found higher rates 
among senior enlisted, though this is likely representative of increasing duration of military 
service and age. 
There are a number of factors that could explain the difference in our results from 
previous studies. Our final model included adjustment for prior back, hip, knee, leg and ankle 
injuries which were not considered in the two studies demonstrating an increased risk for OA 
with contraceptive use. Both of those studies adjusted for BMI, age and smoking. It is worth 
noting that the magnitude of protection we found (19%), after adjusting for a number of factors, is 
similar as identified by Cooley et al. (2003), Dawson et al. (2003) and Samantha et al. (1993) 
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although those findings were not statistically significant. In addition to recently published 
literature suggesting an 18% reduction in ACL injuries among hormonal contraceptive users 
which is one of the major predisposing injuries to early onset OA and was controlled for in our 
final model.  
In addition, the two studies which identified a potential increased risk among 
contraceptive user utilized joint replacement as their outcome of interest. It is possible that 
women with OA who go on to have a joint replacement differ significantly from women who do 
not have a replacement. In addition, it could be suggested these differences may also vary by 
contraceptive use including socio-economics and access to health care. However, both prior 
studies were conducted in Sweden and Norway where there was no cost to access care, similar to 
the health care for active duty military and lifetime ever use was similar among both populations.  
Literature to dates has not considered all types of contraception including patch, ring, 
injection, IUD and implant. When considering only monthly oral contraceptive pills to be 
consistent with prior exposure assessment to date, our results are consistent with the majority of 
prior literature demonstrating no significant association with OA. It is also well established that 
there have been changes in the formulation of the oral contraceptive pill and the exposure 
experienced by Vingard and Hellevik’s participants before 2000 contributes to differences in 
exposure whereby they may not be comparable. When considering the difference in hazards 
among types of contraceptive methods we found a significant reduction in OA among users of the 
patch and IUD (27% and 23% respectively). The protective effect may actually be due, at least in 
part, to confounding by indication. The FDA reports failure rates for the contraceptive patch to 
increase among women who weigh more than 198lbs. The patch is the only contraception method 
with a published weight recommendation and as a result the population who use the patch may 
have lower total body mass (or BMI) and lower BMI is associated with lower rates of OA as 
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compared to overweight or obese women. However, we adjusted for BMI at entry to the Army as 
well as weight standards. 
Our study was only the second to report data on duration of contraceptive use. In our 
final model, we found increasing protection of risk as duration increased. Cooley et al., (2003) 
considered risk by yearly use of contraceptive risk, finding no significant difference with hand 
osteoarthritis at the distal interphalangeal joint 1.01 (95% CI 0.96-1.06). Four studies to date 
collected data on duration of contraceptive use. The others collected information on duration but 
did not report the results (Dennison et al., 1998; Liu et al., 2009; Wei et al., 2011). 
Our findings differ from recent literature, indicating a protective relationship of hormonal 
contraception on OA. In the final model women who ever use contraception, particularly women 
who ever used both progestin only and combined types, as well as women who used any 
contraception for greater than a year had reduced risk of OA (19%, 30% and 21% respectively). 
This is the first known study to date to consider all types of hormonal contraception as well as 
duration by type.  
Limitations 
Non-differential Misclassification Hormonal Contraceptive Use 
Hormonal contraceptive use was determined using pharmacy records. Misclassification 
of hormonal contraceptive use based on pharmacy records will occur in a number of 
circumstances including: servicewomen who fill prescriptions for hormonal contraceptives but do 
not use them and are misclassified as users; servicewomen who have an IUD or Implant inserted 
before they joined the Army and are misclassified as non-users; servicewomen given multiple 
months of contraception coverage that was not documented in their medical records whose 
duration of use will be underestimated. Additionally, servicewomen who pay for hormonal 
contraceptives out of pocket from pharmacies not recorded in the database will be misclassified 
as non-users. We expect this misclassification to be minor due to insurance coverage for 
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hormonal contraceptive by TRICARE which covers these prescriptions at no cost to active duty 
soldiers. Pharmacy records are maintained for all servicewomen by different database than where 
clinical records are maintained. Documentation of contraceptive prescription pick up would not 
be expected to differ by OA and would bias results toward the null.  
Non-differential Misclassification of Continuous Use 
Due to the limitations of PDTS we are unable to identify continuous contraceptive users. 
Continuous use occurs when a woman intentionally discards the last week of inactive pills (the 
last seven pills in a normal 28 day oral contraceptive pack) and immediately starts a new cycle of 
active pills. This electively induces amenorrhea (skipping a menstrual cycle) and exposes the 
woman to additional 91 days (or 125%) exogenous hormones throughout the year compared to a 
traditional pill user. PTDS records do not indicate if a contraception method is being used 
continuously or as prescribed. It is unlikely that differential misclassification of hormonal 
contraception use occurred given the records were collected prospectively prior to OA.  
Non-differential Misclassification of Osteoarthritis 
Soldiers with OA were identified through medical records abstraction using ICD-9 codes. 
Given the variation in severity and fluctuating nature of OA it is possible that OA may not be 
immediately diagnosed. Incident diagnosis may actually represent prevalent cases that reached a 
level of severity the led servicewomen to seek medical care, at which time a clinical diagnosis 
was made. There is also variability between the measurement and classification of OA, where the 
gold standard is through measured structural damage in radiographic imaging as well as presence 
of functional impairment (Richette, Corvol, & Bardin, 2003). Some cases, however, may be 
diagnosed exclusively based upon symptom reporting alone. Both situations would not differ 
according to hormonal contraceptive status given that the pain threshold which encourages a 
woman to seek care would not differ by HC status and there is no well-established link between 
HC and OA where clinicians would differentially examine and diagnose cases. Therefore, both 
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circumstances are expected to represent biases toward the null. Given women can go years with 
OA without diagnosis, and other women with chronic conditions, such as runner’s knee, may be 
incorrectly diagnoses as OA, we expect this misclassification to be moderate.   
Differential Misclassification of Osteoarthritis 
Given the chronic nature of OA, it is possible that differential misclassification of the 
outcome occurred. Women who use hormonal contraception are required to visit their primary 
care provider at least annually for prescription renewals and may seek the care more often than 
non-contraceptive users for prescription changes and concerns. If contraceptive users have more 
frequent medical visits then they may be more likely to mention or be screened for chronic 
medical complaints, including musculoskeletal injuries such as OA. This misclassification 
represents a surveillance bias that would overestimate the effect of contraception use on OA. 
However, all service members are required to complete annual health exams, therefore it is less 
likely that OA would go undiagnosed for prolonged periods of time among non-contraception 
users. As a result, we expect this misclassification to be minimal.  
Selection Bias 
Given the cohort study design, and the fact that information on hormonal contraceptive 
use was collected prior to the occurrence of OA, selection bias is primarily a concern to the extent 
that women may have been differentially lost to follow-up based on hormonal contraceptive use 
and OA. Soldiers are required to have regular medical exams, therefore the main way losses from 
the dataset may occur is due to separation from active duty. Medical documentation is required to 
receive disability benefits from occupational injuries, therefore, it is less likely that a 
servicewoman would not have this documented before discharge from duty, although it is 
possible that women with severe OA may be more likely to leave earlier than no affected women.  
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Confounding 
The large sample size and available data on covariates allowed to address a number of 
important potential confounders; however, uncontrolled confounding is likely still an issue to 
some extent. We evaluated age, BMI at baseline and pregnancy – all confounders that have been 
previously recognized in the literature. Education, rank (which may be a proxy for intensity of 
occupational requirements), were also considered as potential confounding factors, among others. 
We are aware of at least three potential confounders that are not directly available through our 
dataset: BMI throughout career, physical fitness and intensity of unit training and smoking.  
Prior literature suggests that being overweight or obese increases risk for OA. BMI at the 
time of OA diagnosis is not available in the TAIHOD. Although BMI is a potential covariate of 
interest Army requires soldiers to meet height and weight standards, measured at least bi-
annually, creating a more homogenous group of women with a BMI between 18.5-24.9 kg/m2. 
The height/weight standards soldiers are required to maintain provides a degree of control for 
confounding by BMI during their career through restriction. In addition, BMI at accession may be 
an important predictor for BMI prior to military career. 
It is possible that women who are assigned to units that participate in above-average 
strenuous physical activity or high-intensity field training may be more likely to use 
contraceptives for menstrual regulation and may be at increased risk musculoskeletal injury, 
including early chronic degenerative changes given daily physical challenges. The expected result 
of this confounding by training intensity would be to underestimate the protective relationship. 
In addition, smoking is not captured in the TAIHOD though prior studies suggest it may 
be protective against OA. Women who smoke may be less likely to use estrogen containing 
contraceptives due to increased risk of blood clots. Inability to control for smoking would 
underestimate the protective association of contraceptives and OA. 
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Strengths 
Our study adds to the literature in a number of ways. Our study was the second largest 
sample size to date to consider the relationship between contraceptive use and OA. The Army is a 
closely followed population, and the TAIHOD allows for integration of prospectively captured 
contraceptive use by pharmacy records. Prior literature has been limited in its exposure 
assessment and operationalization, having considered only dichotomized ever vs. never use of 
oral contraception. We considered all hormonal types, the length of use, time since last use and a 
combination of type and length of use. In addition, our study included a diverse population 
including young women in many occupational roles whereas studies have been limited to middle 
age-older adults.  
Generalizability 
By its nature, this study focuses on a highly selected study sample – female members of 
the active duty Army. To the extent that the biological mechanism by which hormonal 
contraceptives impact risk of OA does not vary by occupation or race/ethnic factors associated 
with armed service membership, the results of this study may be generalizable to all women. 
Recommendations for Future Research 
Future research should aim to include a number of covariates not considered in this 
analysis including BMI at time of diagnosis, activity level, and participation in athletics, smoking 
and bone density. These factors may identify high risk women in occupational and recreational 
settings which we were unable to access. Women with knee injury are more likely to have 
subsequent OA though our study did not capture lower extremity injury prior to service. Timing 
of pregnancy in relation to contraceptive use and OA warrants additional investigation given the 
significance of results among nulliparous women. Ideally, future work will include detailed 
contraceptive use from menarche through menopause or diagnosis of OA (which ever one comes 
 88 
earlier) including validation of contraceptive use in pharmacy records by self-report to avoid 
misclassification among women who self-discontinue contraceptive use.  
Conclusion 
To date, few studies have evaluated the association between hormonal contraceptive use 
and knee and hip OA. Given the long term consequences OA may have on a service members’ 
fitness, mission readiness and career, it is important to examine possible risk factors. Due to the 
large number of contraceptives users, variety of contraceptive options, increased participation of 
women in the military and the disproportionally high rate at which they are discharged to 
musculoskeletal injury, it is important that the association between hormonal contraceptives and 
OA be fully understood. Results of this study suggest that hormonal contraceptive use may 
reduce OA by 19%. Hormonal contraception is a potentially modifiable risk factor and warrants 
further investigation to integrate in clinical recommendations and injury prevention strategies.  
Human Subjects Protection 
The TAIHOD database was created in 1994 in order to understand risk factors for injury 
within the active duty Army population. All active duty army soldiers are included in the database 
without database specific written consent. Study personnel are trained in privacy protocols and 
electronic study database will be stored with a nonmilitary study identification number on a 
secure server that is password protected. There are no known potential risks to participants, 
expect for accidental breach of confidentiality which is unlikely to occur. Additionally there is no 
known benefit to participating in the study except for advancing science in research involving 
servicewomen. This study was approved by the Institutional Review Boards of the Unites States 
Army Research Institute of Environmental Medicine and the University of Massachusetts 
Amherst. 
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Permission to Access Data 
Permission to access data was granted by the United States Army Research Institute for 
Environmental Medicine Military Performance Division Chief Edward J. Zambraski, Ph.D. and 
TAIHOD director MAJ Owen Hill Ph.D. MPAS, following IRB approval by USARIEM and the 
University of Massachusetts Amherst. 
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CHAPTER 4 
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n % person years n % person years
11,962 5.76 8,031 3.87
1 month in DMDC1 3,544 1.71 295  .  .  . 
Age ≥46 2,186 1.05 8,230 3,124 1.50 8,718
Missing covariates2 2,803 1.35 4,601  .  .  . 
Hysterectomy 684 0.33 3,280 2,547 1.23 6,848
Oophorectomy 446 0.21 2,163 717 0.35 2,226
Menopause 571 0.27 2,956 1,377 0.66 4,206
Hormonal replacement therapy 133 0.06 637 193 0.09 761
Amputation 14 0.01 77 73 0.04 228
Implausible Pregnancy 80 0.04 638  .  .  . 
ACL Injury (before 2002) 1,501 0.72 8,247  .  .  . 
Final Cohort 195,815 703,499
New accessions 2002-2011 5,248 3.95 1,723 1.30
1 month in DMDC1 2,133 1.61 178  .  .  . 
Age ≥46 605 0.46 1,568 439 0.33 907
Missing covariates2 2,348 1.77 3,624  .  .  . 
Hysterectomy 17 0.01 63 538 0.41 1,015
Oophorectomy 6 0.00 34 234 0.18 525
Menopause 28 0.02 96 391 0.29 946
Hormonal replacement therapy 7 0.01 28 81 0.06 240
Amputation 1 0.00 2 40 0.03 114
Implausible Pregnancy 17 0.01 119  .  .  . 
ACL Injury (before 2002) 86 0.06 446  .  .  . 
Final Cohort 127,563 382,104
1 there is no reference to identify if these women had any service prior to 2002
2missing age, education, marital status or race/ethnicity completely
Table 7. Exclusions and Dropout: Contraceptive Use and ACL Injury
Excluded Dropped
All women on active duty
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n % n %
No 193,562 98.85 126,311 99.02
Yes 2,253 1.15 1,252 0.98
Diagnosis and Intervention
X-Ray
No 2,243 99.56 1,211 96.73
Yes 134 5.95 74 5.91
MRI
No 2,146 95.25 1,172 93.61
Yes 221 9.81 112 8.95
Surgical Correction
No 2,040 90.55 1,105 88.26
Yes 332 14.74 178 14.22
*p-value derived from chi-square. p<0.05 unless otherwise noted.
ACL Injury
Table 8. Distribution of ACL Injury
Study Cohort New Accession
195,815 127,563
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n % n %
193,562 98.85 2,253 1.15
New Accession
No 67,251 34.74 1,001 44.43
Yes 126,311 65.26 1,252 55.57
avg SD avg SD
Age at entry(years) 23.37 5.94 24.62 6.17
Age at entry
<20 62,491 32.28 562 24.94
20-24 72,199 37.30 755 33.51
25-29 29,116 15.04 451 20.02
30-34 15,725 8.12 284 12.61
35-39 9,361 4.84 140 6.21
40-45 4,670 2.41 61 2.71
Highest level of education attained
≤High School Graduate 142,066 73.40 1,600 71.02
Some College/Certificate 21,782 11.25 231 10.25
College 23,572 12.18 319 14.16
Graduate Degree 6,142 3.17 103 4.57
Marital Status
Single 126,823 65.52 1,417 62.89
Married 56,991 29.44 689 30.58
Divorced/Widowed/Separated 9,748 5.04 147 6.52
Race
Caucasian 94,102 48.62 1,028 45.63
African American 63,207 32.65 817 36.26
Hispanic 22,028 11.38 209 9.28
American Indian 2,599 1.34 36 1.60
Asian 9,392 4.85 124 5.50
Other 2,234 1.15 39 1.73
Race
African American 130,355 67.35 1,436 63.74
Other 63,207 32.65 817 36.26
Rank
E1-E4 (Private - Specialist) 151,873 78.46 1,587 70.44
E5-E9 (Sergeant-Sergeant Major) 22,063 11.40 377 16.73
Warrant/O1-O3 (Second Luteienant- Captain) 17,134 8.85 234 10.39
O4+ (Major-General) 2,492 1.29 55 2.44
avg SD avg SD
Length of service, years 1.69 3.96 2.34 4.36
Time in Cohort (years)
None 126,311 65.26 1,252 55.57
<2 years 24,660 12.74 332 14.74
2 to <4 years 13,550 7.00 158 7.01
4 to <6 years 8,179 4.23 131 5.81
6 to <8 years 4,606 2.38 79 3.51
8 + years 16,256 8.40 301 13.36
*p-value derived from chi-square , t-test. p<0.05 unless otherwise noted.
Table 9. Correlates of ACL Injury (1 of 2)
No ACL Injury Incident ACL Injury
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n % n %
Pregnancy count
None 163,395 84.41 1,861 82.60
1 23,692 12.24 290 12.87
2 5,451 2.82 78 3.46
3+ 1,024 0.53 24 1.07
Parity
Nulliparous 115,967 59.91 1,318 58.50
Parous 30,167 15.59 392 17.40
Unknown 47,428 24.50 543 24.10
Knee Injury
Never 186,954 96.59 2,103 93.34
Ever 6,608 3.41 150 6.66
Knee Injury Count
None 186,954 96.59 2,103 93.34
1 5,985 3.09 122 5.42
2 571 0.29 27 1.20
3+ 52 0.03 1 0.04
Back/Hip Injury
Never 171,938 88.83 1,925 85.44
Ever 21,624 11.17 328 14.56
Back/Hip Injury Count
None 171,938 88.83 1,925 85.44
1 19,572 10.11 293 13.00
2 1,833 0.95 28 1.24
3+ 219 0.11 7 0.31
Leg/Ankle Injury
Never 184,024 95.07 2,095 92.99
Ever 9,538 4.93 158 7.01
Leg/Ankle Injury Count
None 184,024 95.07 2,095 92.99
1 8,765 4.53 140 6.21
2 732 0.38 18 0.80
3+ 41 0.02 0 0.00
avg SD avg SD
BMI at accession 23.79 3.10 24.53 3.08
BMI at accession, IOM categories
Underweight BMI <18.5 5,104 2.64 32 1.42
Normal weight BMI 18.5-24.9 112,492 58.12 1,147 50.91
Overweight BMI 25.0-30 53,181 27.47 724 32.13
Obese BMI >30 5,357 2.77 100 4.44
Unknown 17,428 9.00 250 11.10
NSAID use
Never 171,522 88.61 1,961 87.04
Ever 22,040 11.39 292 12.96
*p-value derived from chi-square , t-test. p<0.05 unless otherwise noted.
Table 9. Correlates of ACL Injury (2 of 2)
No ACL Injury Incident ACL Injury
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Person years
n
Cases
1 ref 1 ref
0.83 0.74-0.93 0.96 0.85-1.09
1 ref 1 ref
0.86 0.75-0.98 1.07 0.92-1.24
0.81 0.70-0.93 0.88 0.76-1.01
Homronal Contraceptive Method
No use 1 ref 1 ref
Pills, monthly 0.94 0.81-1.10 0.95 0.82-1.11
Pills, seasonal 0.31 0.08-1.25 0.37 0.09-1.50
Patch 0.63 0.38-1.05 0.58 0.35-0.97
Ring 0.8 0.48-1.33 0.72 0.43-1.20
Injection 0.99 0.69-1.42 0.86 0.60-1.22
IUD 0.59 0.39-0.89 0.6 0.40-0.92
Implant 0.91 0.47-1.76 0.94 0.48-1.81
1 ref 1 ref
0.86 0.76-0.97 1 0.88-1.14
0.7 0.54-0.90 0.76 0.58-0.99
Both 0.83 0.69-1.01 0.94 0.76-1.15
Never, Past or Current Use by Type
Never 1 ref 1 ref
Past use combined hormonal contraception 0.87 0.74-1.01 1.1 0.93-1.30
Past use progestin only 0.62 0.43-0.91 0.73 0.50-1.07
Past use both methods 0.94 0.75-1.18 1.11 0.88-1.42
Current use combined hormonal contraception 0.85 0.73-0.99 0.92 0.79-1.09
Current use progestin only 0.77 0.55-1.08 0.79 0.56-1.10
Current user both 0.69 0.52-0.92 0.75 0.55-1.02
Progestin Only
Ever Use, Hormonal Contraceptives
Never
Current
Type, Hormonal Contraceptive Use
Nonuser
Past
378,559
127,563
1,243
Combined Method
Table 11. Hazard Ratio of ACL Injury by Contraceptive Use Among New Accession (1 of 2)
Nonuser
User
Use at Time of ACL Injury
New Accession HR
378,559
127,563
1,243
New Accession HR (adjusted)
Final model adjusted for: age, knee injury, NSAID use, deployment, pregnancy, race ethnicity, back/hip injury 
and new accession
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Person years
n
Cases
Duration
Never 1 ref 1 ref
Short (<90 days) 0.86 0.70-1.04 0.87 0.72-1.06
Medium (90-265 days) 0.83 0.72-0.95 1 0.86-1.16
Long (365+ days) 0.83 0.71-0.97 0.97 0.82-1.16
Never, Past or Current by Duration of Use
Never user 1 ref 1 ref
Past-short (<90 days) 0.85 0.66-1.10 1.05 0.81-1.36
Past-medium (90-365) 0.84 0.71-0.99 1.08 0.91-1.29
Past-long (365+) 0.89 0.71-1.12 1.1 0.86-1.39
Current-short (<90 days) 0.86 0.65-1.15 0.72 0.54-0.96
Current-medium (90-365) 0.81 0.66-0.98 0.92 0.75-1.12
Current-long (365+) 0.79 0.65-0.96 0.93 0.76-1.15
Type by Duration of Use
Never user 1 ref 1 ref
Combined Only-Short 0.95 0.76-1.19 0.95 0.76-1.19
Combined Only-Medium 0.86 0.74-1.00 1.06 0.90-1.25
Combined Only-Long 0.8 0.66-0.97 0.96 0.78-1.17
Progestin Only-Short 0.71 0.44-1.13 0.68 0.43-1.09
Progestin Only-Medium 0.67 0.46-0.98 0.77 0.52-1.38
Progestin Only-Long 0.72 0.44-1.17 0.84 0.67-1.13
Both-Short/Medium 0.76 0.59-0.98 0.87 0.79-1.36
Both-Long 0.92 0.72-1.19 1.04 1.01-1.04
Time Since Last Use (excluding current users n=564)
Never 1 ref 1 ref
Short (<90 days) 1.14 0.92-1.40 1.24 1.0-1.54
Medium (90-265 days) 0.76 0.63-0.92 1 0.81-1.22
Long (365+ days) 0.77 0.63-0.94 0.87 0.70-1.09
Table 11. Hazard Ratio of ACL Injury by Contraceptive Use Among New Accession (2 of 2)
New Accession HR New Accession HR (adjusted)
Final model adjusted for: age, knee injury, NSAID use, deployment, pregnancy, race ethnicity, back/hip injury 
and new accession
378,559 378,559
127,563 127,563
1,243 1,243
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n % person years n % person years
11,471 5.52 8,085 3.89
1 month in DMDC1 3,544 1.71 3544 295  .  .  . 
Age ≥46 2,186 1.05 98764 8,230 3,145 1.51 104947 8,746
Missing covariates2 2,803 1.35 55212 4,601  .  .  . 
Hysterectomy 684 0.33 39355 3,280 2,582 1.24 82281 6,857
Oophorectomy 446 0.21 25952 2,163 719 0.35 26955 2,246
Menopause 571 0.27 35467 2,956 1,375 0.66 50315 4,193
Hormonal replacement therapy 133 0.06 7648 637 192 0.09 9207 767
Amputation 14 0.01 928 77 72 0.03 2739 228
Implausible Pregnancy 80 0.04 7656 638  .  .  .  . 
OA (before 2002) 1,010 0.49 56611 4,718  .  .  .  . 
Final Cohort 196,306 706,978
New accessions 2002-2011 5,177 3.90 1,728 1.30
1 month in DMDC1 2,133 1.61 2133 178  .  .  . 
Age ≥46 605 0.46 18810 1,568 442 0.33 11023 919
Missing covariates2 2,348 1.77 43489 3,624  .  .  . 
Hysterectomy 17 0.01 751 63 538 0.41 12196 1,016
Oophorectomy 6 0.00 403 34 235 0.18 6302 525
Menopause 28 0.02 1156 96 391 0.29 11357 946
Hormonal replacement therapy 7 0.01 333 28 82 0.06 2878 240
Amputation 1 0.00 18 2 40 0.03 1367 114
Implausible Pregnancy 17 0.01 1424 119  .  .  .  . 
OA (before 2002) 15 0.01 833 69  .  .  .  . 
Final Cohort 127,620 381,716
1there is no reference to identify if these women had any service prior to 2002
2missing age, education, marital status or race/ethnicity completely
Table 12. Exclusion and Dropout: Contraceptive Use and Osteoarthritis 
Excluded Dropped
All women on active duty
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n % n %
No 192,363 97.99 127,620 100.00
Yes 3,943 2.01 1,382 1.08
Lower Leg 3,179 80.62 1,013 73.30
     Localized-Primary 514 16.17 160 15.79
     Localized-Secondary 46 1.45 23 2.27
     Localized-Unspecified 541 17.02 194 19.15
     Unspecified 2,078 65.37 636 62.78
Pelvic Region and Thigh 764 19.38 369 26.70
     Localized-Primary 150 19.63 67 18.16
     Localized-Secondary 9 1.18 3 0.81
     Localized-Unspecified 107 14.01 66 17.89
     Unspecified 498 65.18 233 63.14
Osteoarthritis
Table 13. Distribution of Osteoarthritis
Study Cohort New Accession
196,306 127,620
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n % n %
192,363 98.24 3,943 2.01
New Accession
No 66,125 34.38 2,561 64.95
Yes 126,238 65.62 1,382 35.05
avg SD avg SD
Age at entry(years) 23.27 5.85 29.43 6.87
Age at entry
<20 62,678 32.58 377 9.56
20-24 72,379 37.63 763 19.35
25-29 28,986 15.07 736 18.67
30-34 15,121 7.86 1,028 26.07
35-39 8,785 4.57 764 19.38
40-45 4,414 2.29 275 6.97
Highest level of education attained
≤High School Graduate 141,372 73.49 2,542 64.47
Some College/Certificate 21,532 11.19 481 12.20
College 23,436 12.18 654 16.59
Graduate Degree 6,023 3.13 266 6.75
Marital Status
Single 126,870 65.95 1,632 41.39
Married 56,059 29.14 1,823 46.23
Divorced/Widowed/Separated 9,434 4.90 488 12.38
Race
Caucasian 94,011 48.87 1,377 34.92
African American 62,155 32.31 2,006 50.87
Hispanic 21,974 11.42 299 7.58
American Indian 2,604 1.35 46 1.17
Asian 9,406 4.89 141 3.58
Other 2,213 1.15 74 1.88
Race
African American 130,208 67.69 1,937 49.13
Other 62,155 32.31 2,006 50.87
Rank
E1-E4 (Private - Specialist) 151,714 78.87 1,839 46.64
E5-E9 (Sergeant-Sergeant Major) 21,114 10.98 1,492 37.84
Warrant/O1-O3 (Second Luteienant- Captain)17,125 8.90 439 11.13
O4+ (Major-General) 2,410 1.25 173 4.39
avg SD avg SD
Length of service, years 1.62 3.86 5.66 6.27
Time in Cohort (years)
None 126,238 65.62 1,382 35.05
<2 years 24,680 12.83 391 9.92
2 to <4 years 13,499 7.02 267 6.77
4 to <6 years 8,185 4.25 231 5.86
6 to <8 years 4,539 2.36 194 4.92
8 + years 15,222 7.91 1,478 37.48
p-value derived from chi-square , t-test. p<0.05 unless otherwise noted 
Table 14. Correlates of Osteoarthritis (1 of 2)
No OA Incident OA
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n % n %
Pregnancy count
None 162,904 84.69 2,696 68.37
1 23,254 12.09 845 21.43
2 5,227 2.72 325 8.24
3+ 978 0.51 77 1.95
Parity
Nulliparous 116,050 60.33 1,534 38.90
Parous 29,459 15.31 1,247 31.63
Unknown 46,854 24.36 1,162 29.47
Knee Injury
Never 185,769 96.57 3,737 94.78
Ever 6,594 3.43 206 5.22
Knee Injury Count
None 185,769 96.57 3,737 94.78
1 5,967 3.10 183 4.64
2 573 0.30 21 0.53
3+ 54 0.03 2 0.05
Back/Hip Injury
Never 171,233 89.02 2,984 75.68
Ever 21,130 10.98 959 24.32
Back/Hip Injury Count
None 171,233 89.02 2,984 75.68
1 19,153 9.96 839 21.28
2 1,765 0.92 102 2.59
3+ 212 0.11 18 0.46
Leg/Ankle Injury
Never 183,018 95.14 3,540 89.78
Ever 9,345 4.86 403 10.22
Leg/Ankle Injury Count
None 183,018 95.14 3,540 89.78
1 8,582 4.46 369 9.36
2 724 0.38 32 0.81
3+ 39 0.02 2 0.05
avg SD avg SD
BMI at accession 23.77 3.09 24.43 3.38
BMI at accession, IOM categories
Underweight BMI <18.5 5,103 2.65 34 0.86
Normal weight BMI 18.5-24.9 112,256 58.36 1,613 40.91
Overweight BMI 25.0-30 52,431 27.26 1,572 39.87
Obese BMI >30 5,176 2.69 310 7.86
Unknown 17,397 9.04 414 10.50
NSAID use
Never 170,503 88.64 3,455 87.62
Ever 21,860 11.36 488 12.38
p-value derived from chi-square , t-test. p<0.05 unless otherwise noted 
Table 14. Correlates of Osteoarthritis (2 of 2)
No OA Incident OA
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Person years
n
Cases n %
552 40.06 1 ref 1 ref
826 59.94 1.04 0.93-1.16 0.88 0.78-1.00
552 40.06 1 ref 1 ref
435 31.57 1.01 0.89-1.14 0.87 0.7601.00
391 28.37 1.08 0.95-1.23 0.9 0.78-1.03
Homronal Contraceptive Method
No use 987 71.63 1 ref 1 ref
Pills, monthly 237 17.20 1.1 0.95-1.26 1.04 0.90-1.20
Pills, seasonal 9 0.65 1.33 0.69-2.57 1.03 0.53-1.99
Pills, progestin only 1 0.07 0.94 0.13-6.68 0.83 0.17-5.89
Patch 25 1.81 1.15 0.77-1.71 0.94 0.63-1.40
Ring 23 1.67 1.02 0.67-1.54 0.8 0.53-1.22
Injection 35 2.54 1.09 0.78-1.53 0.95 0.68-1.34
IUD 49 3.56 0.99 0.75-1.33 0.77 0.58-1.04
Implant 12 0.87 0.84 0.47-1.49 0.82 0.46-1.45
552 40.06 1 ref 1 ref
528 38.32 1.02 0.90-1.15 0.91 0.80-1.03
98 7.11 1.04 0.84-1.29 0.9 0.72-1.12
Both 200 14.51 1.1 0.93-1.29 0.79 0.66-0.94
Never, Past or Current Use by Type
Never 552 40.06 1 ref 1 ref
Past use combined hormonal contraception 282 20.46 0.99 0.86-1.15 0.89 0.76-1.04
Past use progestin only 46 3.34 1.01 0.75-1.37 0.91 0.67-1.23
Past use both methods 107 7.76 1.05 0.85-1.29 0.78 0.62-0.97
Current use combined hormonal contraception 246 17.85 1.05 0.91-1.23 0.93 0.80-1.09
Current use progestin only 52 3.77 1.06 0.80-1.41 0.88 0.66-1.17
Current user both 93 6.75 1.15 0.93-1.44 0.79 0.62-1.00
Final model adjusted for: age,  knee, back/hip, leg/ankle injury, nsaid use, new accession, deployment, education, BMI, marital 
status, race, parity and rank
Type, Hormonal Contraceptive Use
Nonuser
Combined Method
Progestin Only
Table 16. Hazard Ratio of Osteoarthritis by Contraceptive Use Among New Accessions (1 of 2)
1,378
New Accession HR
OA Cases 368,736
New Accession HR (adjusted)
368,736
127,620
1,378
User
Ever Use, Hormonal Contraceptives
Never
Past
Current
1,378 127,620
Use at Time of OA Diagnosis
Nonuser
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Person years
n
Cases n %
Duration
Never 552 40.06 1 ref 1 ref
Short (<90 days) 120 8.71 1.02 0.84-1.23 0.93 0.77-1.13
Medium (90-265 days) 376 27.29 1 0.88-1.14 0.9 0.78-1.03
Long (365+ days) 320 23.22 1.1 0.95-1.26 0.83 0.71-0.97
Never, Past or Current Use by Duration of Use
Never user 552 40.06 1 ref 1 ref
Past-short (<90 days) 79 5.73 1.05 0.83-1.33 1.03 0.81-1.31
Past-medium (90-365) 230 16.69 0.97 0.83-1.12 0.86 0.72-1.02
Past-long (365+) 126 9.14 1.06 0.87-1.29 0.78 0.63-0.96
Current-short (<90 days) 51 3.70 0.97 0.73-1.29 0.82 0.61-1.09
Current-medium (90-365) 146 10.60 1.06 0.88-1.27 0.96 0.80-1.16
Current-long (365+) 194 14.08 1.12 0.95-1.33 0.86 0.72-1.03
Type by Duration of use
Never user 552 40.06 1 ref 1 ref
Combined Only-Short 84 6.10 0.97 0.77-1.22 0.89 0.70-1.12
Combined Only-Medium 260 18.87 1.02 0.88-1.18 0.96 0.83-1.12
Combined Only-Long 184 13.35 1.05 0.88-1.24 0.84 0.70-1.01
Progestin Only-Short 24 1.74 1.05 0.70-1.58 0.94 0.62-1.42
Progestin Only-Medium 42 3.05 0.95 0.69-1.30 0.85 0.62-1.17
Progestin Only-Long 32 2.32 1.18 0.82-1.69 0.91 0.62-1.31
Both-Short/Medium 96 6.97 1.02 0.82-1.27 0.8 0.64-1.00
Both-Long 104 7.55 1.18 0.95-1.46 0.77 0.61-0.97
Time Since Last Use (excluding current users n=973)
Never 552 55.93 1 ref 1 ref
Short (<90 days) 97 9.83 1.04 0.89-1.37 0.91 0.72-1.14
Medium (90-265 days) 149 15.10 0.88 0.74-1.06 0.84 0.69-1.02
Long (365+ days) 189 19.15 1.05 0.89-1.25 0.8 0.66-0.97
Final model adjusted for: age,  knee, back/hip, leg/ankle injury, nsaid use, new accession, deployment, education, BMI, marital 
status, race, parity and rank
1,378 127,620 127,620
1,378 1,378
New Accession HR New Accession HR (adjusted)
OA Cases 368,736 368,736
Table 16. Hazard Ratio of Osteoarthritis by Contraceptive Use Among New Accessions (2 of 2)
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 Amputation
879.7 ICD-9 Bilateral [any level], complicated
895.0 ICD-9 Amputation of toe, without mention of complication
895.1 ICD-9 Complicated amputation of toe
896.0 ICD-9 Unilateral foot, without mention of complication
896.1 ICD-9 Unilateral, complicated
896.2 ICD-9 Bilateral, without mention of complication Excludes:one foot and other leg (897.6-897.7)
896.3 ICD-9 Bilateral, complicated
897.0 ICD-9 Unilateral, below knee, without mention of complication
897.1 ICD-9 Unilateral, below knee, complicated
897.2 ICD-9 Unilateral, at or above knee, without mention of complication
897.3 ICD-9 Unilateral, at or above knee, complicated
897.4 ICD-9 Unilateral, level not specified, without mention of complication
897.5 ICD-9 Unilateral, level not specified, complicated
897.6 ICD-9 Bilateral [any level], without mention of complication 
V49.0 ICD-9 Unspecified level
V49.71 ICD-9 Great toe
V49.72 ICD-9 Other toe(s)
V49.73 ICD-9 Foot
V49.74 ICD-9 Ankle Disarticulation of ankle
V49.75 ICD-9 Below knee
V49.76 ICD-9 Above knee Disarticulation of knee
V49.77 ICD-9 Hip Disarticulation of hip
01404 CPT Amputation at Knee 
27290 CPT Amputation on the Pelvis and Hip Joint
27295 CPT Upper Amputation Procedure on the Pelvis and Hip Joint
27880 CPT Disarticulation of Knee
27881 CPT Under Amputation Procedures on the Leg (Tibia and Fibula) and Ankle Joint
27882 CPT Under Amputation Procedures on the Leg (Tibia and Fibula) and Ankle Joint
27888 CPT Under Amputation Procedures on the Leg (Tibia and Fibula) and Ankle Joint
27889 CPT Under Amputation Procedures on the Leg (Tibia and Fibula) and Ankle Joint
28800 CPT Under Amputation Procedures on the Foot and Toes
28805 CPT Under Amputation Procedures on the Foot and Toes
28810 CPT Under Amputation Procedures on the Foot and Toes
28820 CPT Under Amputation Procedures on the Foot and Toes
28825 CPT Under Amputation Procedures on the Foot and Toes
84.10 Procedure Lower limb amputation not otherwise specified
84.11 Procedure Amputation of toe
84.12 Procedure Amputation through foot 
84.13 Procedure Disarticulation of the ankle 
84.14 Procedure Amputation through malleoli of tibia and fibula 
84.15 Procedure Amputation below the knee 
84.16 Procedure Disarticulation of the knee
84.17 Procedure Amputation above the knee
84.18 Procedure Disarticulation of hip
84.19 Procedure Abdominopelvic amputation
Hormone Replacement Therarpy
V07.4 ICD-9 Hormone replacement therapy (postmenopausal)
V07.5 ICD-9 Prophylactic use of agents affecting estrogen recrptors and estrogen levels
ICD-9, PROCEDURE AND CPT CODES (1 OF 4)
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Hysterectomy
58150 CPT Under Hysterectomy Procedures
58152 CPT Under Hysterectomy Procedures
58180 CPT Under Hysterectomy Procedures
58200 CPT Under Hysterectomy Procedures
58210 CPT Under Hysterectomy Procedures
58260 CPT Under Hysterectomy Procedures
58262 CPT Under Hysterectomy Procedures
58263 CPT Under Hysterectomy Procedures
58267 CPT Under Hysterectomy Procedures
58270 CPT Under Hysterectomy Procedures
58275 CPT Under Hysterectomy Procedures
58280 CPT Under Hysterectomy Procedures
58285 CPT Under Hysterectomy Procedures
68.31 Procedure Laparoscopic supracervical hysterectomy [LSH]
68.39 Procedure Other and unspecified subtotal abdominal hysterectom
68.4 Procedure Total abdominal hysterectomy
68.51 Procedure Vaginal hysterectomy
68.59 Procedure Other and unspecified vaginal hysterectomy
68.7 Procedure Radical vaginal hysterectomy
68.8 Procedure Pelvic evisceration
68.6 Procedure Radical abdominal hysterectomy
68.9 Procedure Other and unspecified hysterectomy
Menopause
627.1 ICD-9 Postmenopausal bleeding
627.2 ICD-9 Symptomatic menopausal or female climacteric states
627.3 ICD-9 Postmenopausal atrophic vaginitis
627.4 ICD-9 Symptomatic states associated with artificial menopause 
627.8 ICD-9 Other specified menopausal and postmenopausal disorders 
627.9 ICD-9 Unspecified menopausal and postmenopausal disorder 
V49.81 ICD-9 Asymptomatic postmenopausal status (age-related) (natural)
Oopherectomy
58720 CPT Salpingo-oopherectomy, complete or partial, unilateral or bilaterl (separate procedure)
65.09 Procedure Other oophorectomy
65.31 Procedure Other unilateral oophorectomy
65.39 Procedure Other unilateral oophorectomy
65.41 Procedure Laparoscopic unilateral salpingo-oophorectomy
65.49 Procedure Other unilateral salpingo-oophorectomy
65.51 Procedure Other removal of both ovaries at same operative episode
65.52 Procedure Other removal of remaining ovary
65.53 Procedure Laparoscopic removal of both ovaries at same operative episode
65.54 Procedure Laparoscopic removal of remaining ovary
65.61 Procedure Other removal of both ovaries and tubes at same operative episode Excludes:that by laparoscope (65.63)
65.62 Procedure Other removal of remaining ovary and tube Removal of solitary ovary and tube Excludes: that by laparoscope (65.64)
65.63 Procedure Laparoscopic removal of both ovaries and tubes at same operative episode
65.64 Procedure Laparoscopic removal of remaining ovary and tube
ICD-9, PROCEDURE AND CPT CODES (2 OF 4)
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Pregnacy
V22.0 ICD-9 Normal first pregnancy
V22.1 ICD-9 Normal other pregnancy
V22.2 ICD-9 Pregnancy state incidental
Delivery
648 ICD-9 Other current condition in pregnancy (.0-.9)
650 ICD-9 Normal delivery
V24.0 ICD-9 Postpartum care and exam- immediately after delivery
V27.0 ICD-9 Outcome of delivery
73 Procedure Procedures inducing or assiting delivery non-ectopic (includes .01, .09, .1, .21,.22, .3, .4, .51,.59 .6, .8, .91,.93,.94,.99)
74 Procedure Cesarean section (includes .0, .1,.2,.3,.4,.91, .99) 
Postpartum Care
V24.2 ICD 9 Postpartum care and exam -routine postpartum follow up
Pregnancy Loss
633 ICD-9 Ectopic Pregnancy (inclide .00, .01, .10,.11,.20, .21, .80,.81, .90,.91)
634 ICD-9 Spotaneous abortion (includes .0-.9)
637 ICD-9 Unspecified abortion (includes .0-.9)
69 Procedure Theraputic abortion, spontaenous abortion or ectopic (includes .01, .02, .51, .52, .59)
Knee Injury
717.0 ICD-9 Old bucket handle
717.1 ICD-9 Derange ant. horn medial meniscus
717.2 ICD-9 Derange post. horn medial meniscus
717.3 ICD-9 Derange unspec meniscus
717.40 ICD-9 Derange lateral meniscus unspecified
717.41 ICD-9 Derange lateral meniscus-bucket handle tear 
717.42 ICD-9 Derange lateral meniscus- anterior horn
717.43 ICD-9 Derange lateral meniscus-posterior horn
717.49 ICD-9 Derange lateral meniscus-other
717.5 ICD-9 Derangement of meniscus, not elsewhere classified
717.5 ICD-9 Derange of meniscus
717.6 ICD-9 Loose body in knee
717.7 ICD-9 Chondromalacia of patella
717.81 ICD-9 Other internal derange of knee-old disruption LCL
717.82 ICD-9 Other internal derange of knee-old disruption MCL
717.84 ICD-9 Other internal derange of knee-old disruption PCL
717.85 ICD-9 Other internal derange of knee-old disruption other
717.89 ICD-9 Other internal derange of knee
717.9 ICD-9 Unspec internal derange of knee
719.46 ICD-9 Patellar Femoral Pain Syndrome "runners knee"
726.60 ICD-9 Enthesopathy of knee, unspecified
726.61 ICD-9 Pes anserinus tendinitis or bursitis
726.62 ICD-9 Tibial collateral ligament bursitis
726.63 ICD-9 Fibular collateral ligament bursitis
726.64 ICD-9 Patellar tendinitis
726.64 ICD-9 Patellar tendititis/tendinosis ‘jumpers knee’ 
726.65 ICD-9 Prepatellar bursitis
726.69 ICD-9 Other enthesopathy of knee
727.51 ICD-9 Synovial cyst of popliteal space
727.83 ICD-9 Plica syndrome
728.89 ICD-9 Other disorders of muscle, ligament, and fascia
733.92 ICD-9 Chondromalacia of knee excluded patella (717.7)
822.1 ICD-9 Fracture of patella-open
836 ICD-9 Dislocation of Knee (0,.1,.2,.3, .4)
836.5 ICD-9 Other dislocation of knee, closed (.00, .01, .02, .03, .04, .09)
844.0 ICD-9 Sprains and strains of knee and leg- Lateral collateral ligament of knee
844.1 ICD-9 Sprains and strains of knee and leg-medial collateral ligament of the 
844.3 ICD-9 Sprain of superior tibulofibular joint/ligament 
844.8 ICD-9 Sprains and strains of knee and leg-Other specified sites of knee and leg
844.9 ICD-9 Sprains and strains of knee and leg- Unspecified site of knee and leg
882.0 ICD-9 Fracture of patella-closed
ICD-9, PROCEDURE AND CPT CODES (3 OF 4)
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Back/Hip Injury
718.85 ICD-9 Acetabular labral tear 
722.10 ICD-9 Displacement of thoracic or lumbar intervertebral disc without myelopathy-lumbar intervertebral disc without myelopathy 
722.11 ICD-9 Displacement of thoracic or lumbar intervertebral disc without myelopathy-Thoracic intervertebral disc without myelopathy
724.2 ICD-9 Lumbago’ includes low back pain, low back syndrome, lumbalgia 
724.6 ICD-9 Disorders of sacrum- ankylosis and instability of lumbosacral and sacroiliac 
733.96 ICD-9 Stress fracture femoral neck
733.97 ICD-9 Stress fracture shaft of femur
733.98 ICD-9 Stress fracture pelvis includes pubic ramus
756.11 ICD-9 Spondyloysis-lumbosacral region 
846.0 ICD-9 Sprain and strain of sacroiliac region Lumbosacral (joint) (ligament)
846.1 ICD-9 Sprain and strain of sacroiliac region  Sacroiliac ligament
846.2 ICD-9 Sprain and strain of sacroiliac region  Sacrospinatus (ligament)
846.3 ICD-9 Sprain and strain of sacroiliac region  Sacrotuberous (ligament)
846.8 ICD-9 Sprain and strain of sacroiliac region Other specified sites of sacroiliac region
846.9 ICD-9 Sprain and strain of sacroiliac region Unspecified site of sacroiliac region
Leg/Ankle Injury
715.17 ICD-9 OA ankle and foot
715.27 ICD-9 OA ankle and foot
715.37 ICD-9 OA ankle and foot
715.97 ICD-9 OA ankle and foot
726.71 ICD-9 Achilles tendinitis or tendinosis, also includes bursitis 
726.72 ICD-9 Tibialis tendinitis/tendinosis 
728.71 ICD-9 Plantar fascititis fibromatosis- includes contracture and traumatic (
729.72 ICD-9 Nontraumatic compartment syndrome of lower extremity 
733.93 ICD-9 Stress fracture tibia/fibula
733.94 ICD-9 Stress fratcure metatarsals
V49.74 ICD-9 Disarticulation of the ankle 
ACL Injury
717.83 ICD-9 Old disruption of anterior cruciate ligament
844.2 ICD-9 Sprains and strains of knee and leg-cruiciate ligament, acl injury
Osteoarthritis
715.15 ICD-9 Osteoarthrosis, localized, primary-pelvic region and thigh
715.16 ICD-9 Osteoarthrosis, localized, primary-lower leg (not ankle)
715.25 ICD-9 Osteoarthrosis, localized, secondary-pelvic region and thigh
715.26 ICD-9 Osteoarthrosis, localized, secondary-lower leg (not ankle)
715.35 ICD-9 Osteoarthrosis, localized, not specified whether primary or secondary-pelvic region and thigh
715.36 ICD-9 Osteoarthrosis, localized, not specified whether primary or secondary-lower leg (not ankle)
715.95 ICD-9 Osteoarthrosis, unspecified whether generalized or localized-pelvic region and thigh
715.96 ICD-9 Osteoarthrosis, unspecified whether generalized or localized-lower leg (not ankle)
ICD-9, PROCEDURE AND CPT CODES (4 OF 4)
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